Polymorphic forms of 5H-pyrrolo [2, 3-b] pyrazine derivatives, methods of preparation and uses thereof

Through the citrate form of compound A, the purity and stability problems in drug preparation are solved, high bioavailability and low hygroscopicity are achieved, and suitable for the treatment of inflammatory disorders, autoimmune diseases and cancer, ensuring the long-term drug Stability and efficacy.

CN119072480AInactive Publication Date: 2024-12-03BEIGENE LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380035632.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-24
Filing Date
2023-04-24
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to provide high purity and stability of Compound A in drug formulation, especially to maintain its low hygroscopicity over a long-term shelf life, and the relationship between bioavailability and specific salts is unknown, affecting the absorption and efficacy of the drug.

Method used

By providing the citrate form of Compound A, high bioavailability and low hygroscopicity are achieved, suitable for pharmaceutical formulations, and show good fluidity and long-term stability in industrial production.

Benefits of technology

The citrate form of Compound A significantly improves the bioavailability and stability of the drug, ensures the quality and efficacy of the drug in the long term, and is suitable for the treatment of inflammatory disorders, autoimmune diseases and cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The present invention relates to salts of the HPK1 inhibitor (hereinafter referred to as' Compound A '), preferably citrate salts, and crystalline forms thereof. The invention also relates to a preparation process and use of the salts and crystalline forms of Compound A.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to polymorphs of a hematopoietic progenitor kinase 1 (HPK1) inhibitor (hereinafter referred to as "Compound A"), preferably polymorphs of a citrate salt of the compound. The present invention also relates to a preparation process and use of a salt and a crystalline form of Compound A. Background Art

[0002] The compound 4-[2-(2,8-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]-N,N,2-trimethylbenzamide (Compound A) is shown in the following formula:

[0003]

[0004] WO 2021000925 discloses a series of compounds, including Compound A. Compound A is described as an HPK1 inhibitor that can be used to treat a variety of diseases, including cancer.

[0005] In order to make a pharmaceutical product, the active ingredient must have high purity and stability. In particular, in order to maintain high stability over a long shelf life, the active ingredient must have low hygroscopicity so that the effect of moisture on quality can be avoided. Therefore, it is necessary to manufacture compound A in a free form or a crystalline form of a salt in pursuit of improved properties.

[0006] For solid formulations containing a desired active ingredient for oral administration, the active ingredient needs to have a desired bioavailability so that the active ingredient can be absorbed into the blood circulation of the body as much as possible. However, the relationship between bioavailability and a specific salt is unknown in the art, and new salts of Compound A with sufficient bioavailability are highly desired.

[0007] HPK1 is a member of the MAP4K family, which includes MAP4K1 / HPK1, MAP4K2 / GCK, MAP4K3 / GLK, MAP4K4 / HGK, MAP4K5 / KHS, MAP4K6 / MINK [Hu, MC et al., Genes Dev, 1996. 10: p. 2251-64]. HPK1 regulates different functions of various immune cells, and its kinase activity has been demonstrated in T cell receptor (TCR) [Liou J. et al., Immunity, 2000. 12(4): 399-408], B cell receptor (BCR) [Liou J. et al., Immunity, 2000. 12(4): 399-408], transforming growth factor receptor (TGF-βR) [Wang, W. et al., J Biol Chem, 1997. 272(36): 22771-5; Zhou, G. et al., J Biol Chem, 1999. 274(19): 13133-8], and Gs-coupled PGE2 receptors (EP2 and EP4) [Ikegami, R. et al., J Biol Chem, 1998. 276(2): 13133-8], and Gs-coupled PGE2 receptors (EP2 and EP4) [Ikegami, R. et al., J Biol Chem, 1998. 277(36): 22771-5; Zhou, G. et al., J Biol Chem, 1998. 276(2): 13133-8], and Gs-coupled PGE2 receptors (EP2 and EP4) [Ikegami, R ... HPK1 is induced after activation of the TCR-induced AP-1-dependent gene transcription [Liou J. et al., Immunity, 2000. 12(4): 399-408], and this blockade is considered to be a negative inhibitory mechanism of TCR-induced IL-2 gene transcription [S. Sawasdikosol. et al., Immunol Res, 2012. 54: 262-265].

[0008] HPK1- / -T cells in vitro have a lower threshold for TCR activation, can proliferate robustly, produce increased amounts of Th1 cytokines, and HPK1- / - mice experience increasingly severe autoimmune symptoms [S. Sawasdikosol. et al., Immunol Res [Immunol Research], 2012.54: pp. 262-265]. In humans, HPK1 is downregulated in peripheral blood mononuclear cells of patients with psoriatic arthritis or T cells of patients with systemic lupus erythematosus (SLE) [Batliwalla FM et al., Mol Med [Molecular Medicine], 2005.11 (1-12): pp. 21-9], indicating that reduced HPK1 activity may contribute to the patient's autoimmunity. In addition, HPK1 can also regulate anti-tumor immunity via T cell-dependent mechanisms. In a Lewis lung cancer tumor model that produces PGE2, tumors in HPK1 knockout mice develop more slowly than in wild-type mice [U.S. Patent Application No. 2007 / 0087988]. HPK1-deficient T cells are more effective than wild-type T cells in controlling tumor growth and metastasis [Alzabin, S. et al., Cancer Immunol Immunother, 2010. 59(3): 419-29]. Similarly, BMDCs from HPK1 knockout mice are more effective in enhancing T cell responses to eradicate Lewis lung carcinoma than wild-type BMDCs [Alzabin, S. et al., J Immunol, 2009. 182(10): 6187-94]. In summary, HPK1 may be a good target for enhancing anti-tumor immunity.

[0009] Therefore, there is still a need to find new solid forms of Compound A or its salts that meet the above-mentioned requirements for pharmaceutical formulations. Summary of the invention

[0010] The present application discloses an invention that addresses the aforementioned challenges and needs by providing stable salts of Compound A, particularly citrate salts of Compound A, which salts exhibit desirable crystallinity suitable for pharmaceutical formulations as well as improved bioavailability.

[0011] In addition, the inventors have found that, among the various salts of Compound A, the citrate salt of Compound A exhibits unexpectedly high bioavailability, which makes the citrate salt of Compound A suitable for pharmaceutical formulations.

[0012] Surprisingly, the salt of compound A (preferably the citrate of compound A, even more preferably the crystal of the citrate) is a solid with very low hygroscopicity, which leads to good flowability for industrial production. The salt of compound A (preferably the citrate of compound A, even more preferably the crystal of the citrate) can be used in the process of large-scale production of formulations without hygroscopicity problems.

[0013] Even more surprising is that Citrate Type A exhibits excellent long-term stability in the 3-month experiment. Based on the current data, we can also expect that Citrate Type A should have very good long-term stability, such as 6-month long-term stability, 12-month long-term stability, 24-month long-term stability, and 36-month long-term stability.

[0014] Prior to the filing date of the present application, the inventors of the present application unexpectedly discovered that only citric acid can form a crystalline form with Compound A having the desired crystallinity, high stability, and low hygroscopicity.

[0015] Aspect 1. A pharmaceutically acceptable salt of 4-[2-(2,8-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]-N,N,2-trimethylbenzamide, wherein the pharmaceutically acceptable salt is one or more inorganic salts or one or more organic salts.

[0016] Aspect 2. The salt according to aspect 1, which is in a solid state.

[0017] Aspect 3. The salt according to aspect 1 or 2, wherein the salt is an inorganic salt selected from the group consisting of hydrochloride, sulfate, phosphate, hydrobromide and / or nitrate; or an organic salt selected from the group consisting of fumarate, tartrate (L-tartrate, D-tartrate or DL-tartrate), laurate, stearate, gentisate, nicotinate, aspartate (L-aspartate), succinate, adipate, malate (L-malate), citrate, maleate, glycolate, gluconate (D-gluconate), lactate (L-lactate), acetate, benzenesulfonate, methanesulfonate, mesylate, benzoate, naphthylate, and / or oxalate;

[0018] Preferably, the salt is selected from hydrochloride, sulfate, phosphate, hydrobromide, fumarate, tartrate (L-tartrate, D-tartrate or DL-tartrate), aspartate (L-aspartate), succinate, malate (L-malate), citrate, maleate, methanesulfonate or mesylate;

[0019] More preferably, the salt is selected from L-malate, citrate or succinate;

[0020] Even more preferably, the salt is citrate.

[0021] Aspect 4. The salt according to aspect 3, wherein the salt is a compound having formula (I):

[0022]

[0023] wherein n is a number from about 0.2 to about 2.0.

[0024] Aspect 5. The salt according to aspect 4, wherein n is a number from about 0.3 to about 1.5; preferably n is a number selected from the group consisting of: 0.3±0.1, 0.5±0.1, 0.7±0.1, 1.0±0.1 and 1.5±0.1;

[0025] Preferably, n is a number selected from the group consisting of 0.3±0.05, 0.5±0.05, 0.6±0.05, 0.7±0.05, 0.8±0.05, 1.0±0.05, 1.1±0.05 and 1.5±0.05;

[0026] More preferably, n is 0.25-0.35, 0.55-0.65, 0.65-0.75, 0.75-0.85, 0.85-0.95, 0.95-1.05, 1.05-1.15 or 1.45-1.55;

[0027] Even more preferably, n is about 0.3, 0.33, 0.40, 0.44, 0.45, 0.50, 0.55, 0.56, 0.60, 0.63, 0.65, 0.66, 0.67, 0.70, 0.75, 0.76, 0.80, 0.85, 0.90, 0.95, 0.96, 0.97, 0.98, 0.99, 1.0, 1.01, 1.02, 1.03, 1.04, 1.05, 1.06, 1.1, 1.45, 1.5, 1.55, 1.67, 1.8, 1.90, 1.95, 2.0.

[0028] Aspect 6. The salt according to aspect 3, wherein the salt is L-malate.

[0029] Aspect 7. The salt according to aspect 6, wherein the salt is a compound having formula (II):

[0030]

[0031] wherein m is a number from about 0.5 to about 2.0.

[0032] Aspect 8. The salt according to aspect 7, wherein m is a number from about 0.5 to about 1.5;

[0033] Preferably m is a number selected from the group consisting of 0.5±0.1, 0.7±0.1, 1.0±0.1 and 1.5±0.1;

[0034] More preferably, m is a number selected from the group consisting of 0.5±0.05, 0.6±0.05, 0.7±0.05, 0.8±0.05, 0.9±0.05, 1.0±0.05, 1.1±0.05, 1.2±0.05 and 1.5±0.05;

[0035] Even more preferably, m is 0.95-1.05, 1.05-1.15, 1.15-1.25 or 1.45-1.55;

[0036] Even more preferably, m is about 0.45, 0.50, 0.55, 0.95, 0.98, 0.99, 1.0, 1.01, 1.02, 1.05, 1.06, 1.07, 1.08, 1.09, 1.10, 1.11, 1.12, 1.13, 1.14, 1.15, 1.16, 1.17, 1.18, 1.19, 1.20, 1.3, 1.4, 1.45 or 1.5.

[0037] Aspect 9. The salt according to aspect 3, wherein the salt is succinate.

[0038] Aspect 10. The salt according to aspect 9, wherein the salt is a compound having formula (III):

[0039]

[0040] wherein r is a number from about 0.2 to about 2.0.

[0041] Aspect 11. The salt according to aspect 10, wherein r is a number from about 0.5 to about 1.5;

[0042] Preferably r is a number selected from the group consisting of: 0.5±0.1, 0.7±0.1, 1.0±0.1 and 1.5±0.1;

[0043] More preferably, r is a number selected from the group consisting of 0.5±0.05, 0.6±0.05, 0.7±0.05, 0.8±0.05, 0.9±0.05, 1.0±0.05, 1.1±0.05, 1.2±0.05 and 1.5±0.05;

[0044] Even more preferably, r is 0.95-1.05, 1.05-1.15, 1.15-1.25 or 1.45-1.55;

[0045] Even more preferably, r is 0.45, 0.50, 0.55, 0.95, 0.98, 0.99, 1.0, 1.01, 1.02, 1.05, 1.06, 1.07, 1.08, 1.09, 1.10, 1.11, 1.12, 1.13, 1.14, 1.15, 1.16, 1.17, 1.18, 1.19, 1.20, 1.3, 1.4, 1.45 or 1.5.

[0046] Aspect 12. A pharmaceutical composition comprising a therapeutically effective amount of the salt according to any one of aspects 1 to 11, and optionally one or more pharmaceutically acceptable carriers.

[0047] Aspect 13. A method for treating or preventing a disorder or disease selected from an inflammatory disorder, an autoimmune disease, or cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of the salt of any one of Aspects 1-11, or the pharmaceutical composition of Aspect 12.

[0048] Aspect 14. A crystalline form having formula IV

[0049]

[0050] wherein [acid] is selected from the group consisting of organic acids and inorganic acids;

[0051] [Solvent] is selected from H2O or an organic solvent;

[0052] s is a number from about 0.0 to about 5.0;

[0053] t is a number from about 0.0 to about 5.0.

[0054] Aspect 15. The crystalline form of Aspect 14, wherein [acid] is selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, nitric acid, fumaric acid, L-tartaric acid, D-tartaric acid, DL-tartaric acid, lauric acid, stearic acid, gentisic acid, niacin, aspartic acid, succinic acid, adipic acid, malic acid (L-malic acid), citric acid, maleic acid, ascorbic acid (L-ascorbic acid), glycolic acid, gluconic acid (D-gluconic acid), lactic acid (L-lactic acid), acetic acid, benzenesulfonic acid, methanesulfonic acid, benzoic acid, naphthalenesulfonic acid, and / or oxalic acid;

[0055] Preferably, [acid] is selected from hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, fumaric acid, tartaric acid (L-tartaric acid or D-tartaric acid), aspartic acid (L-aspartic acid), succinic acid, malic acid (L-malic acid), citric acid, maleic acid, methanesulfonic acid;

[0056] More preferably, [acid] is selected from L-malic acid, citric acid, succinic acid;

[0057] Even more preferably [the acid] is selected from citric acid.

[0058] Aspect 16. The crystalline form of any one of Aspects 14-15, wherein s is a number from about 0 to about 1.5;

[0059] Preferably s is a number selected from the group consisting of 0.3±0.1, 0.5±0.1, 0.7±0.1, 1.0±0.1 and 1.5±0.1;

[0060] More preferably s is a number selected from the group consisting of 0.3±0.05, 0.5±0.05, 0.6±0.05, 0.7±0.05, 0.8±0.05, 1.0±0.05, 1.1±0.05, 1.2±0.05 and 1.5±0.05;

[0061] Even more preferably, s is a number selected from the group consisting of 0.25-0.35, 0.55-0.65, 0.65-0.75, 0.75-0.85, 0.85-0.95, 0.95-1.05, 1.05-1.15, 1.15-1.25 or 1.45-1.55;

[0062] Even more preferably, s is 0.55-0.65, 0.65-0.75, 0.75-0.85, 0.85-0.95, 0.95-1.05, 1.05-1.15 or 1.45-1.55; even more preferably, s is 0.3, 0.33, 0.40, 0.44, 0.45, 0.50, 0.55, 0.56, 0.60, 0.63, 0.65, 0.66, 0.67, 0.70, 0.75, 0.76, 0.80, 0.85, 0. .90, .95, .96, .97, .98, .99, 1.0, 1.01, 1.02, 1.03, 1.04, 1.05, 1.06, 1.07, 1.08, 1.09, 1.1, 1.11, 1.12, 1.13, 1.14, 1.15, 1.16, 1.17, 1.18, 1.19, 1.20, 1.3, 1.4, 1.45, 1.5, 1.55, 1.67, 1.8, 1.90, 1.95, or 2.0.

[0063] Aspect 17. The crystalline form of aspect 14, wherein [solvent] is selected from the group consisting of an inorganic solvent selected from the group consisting of H2O, MeOH, EtOH, n-PrOH, i-PrOH, 1-butanol, sec-BuOH, tert-BuOH CF3CH2OH, acetone, toluene, THF, MeOAc, EtOAc, PrOAc, dioxane, chloroform, DCM, butanone and MeCN or a combination of any of the foregoing inorganic solvents;

[0064] Preferably, [Solvent] is selected from the group consisting of an inorganic solvent selected from the group consisting of H2O, MeOH, EtOH, n-PrOH, i-PrOH, 1-BuOH, sec-BuOH, tert-BuOH, CF3CH2OH, acetone, toluene, THF, MeOAc, EtOAc, PrOAc, dioxane, chloroform, DCM, butanone, MeCN, (H2O and EtOH), (H2O and acetone) or (H2O and MeCN);

[0065] Even more preferably, the solvent is selected from H2O, MeOH, EtOH, n-PrOH, i-PrOH, CF3CH2OH or (H2O and EtOH) or (H2O and MeOH) or (H2O and i-PrOH) or (H2O and n-PrOH) or (H2O, n-PrOH and i-PrOH) or any combination thereof.

[0066] Aspect 18. The crystalline form of any one of Aspects 14 and 17, wherein t is a number from about 0 to about 3;

[0067] Preferably t is a number selected from the group consisting of: 0, 0.5±0.2, 1.0±0.2, 1.5±0.2, 2.0±0.2, 2.5±0.2, 3.0±0.2;

[0068] More preferably, t is 0-0.13, 0.13-0.25, 0.25-0.5, 0.5-0.67, 0.67-0.75, 0.75-1, 1-1.5, 1.5-2, 2-2.5, 2.5-3;

[0069] Even more preferably, t is about 0, 0.1, 0.14, 0.17, 0.2, 0.25, 0.3, 0.4, 0.45, 0.5, 0.50, 0.55, 0.57, 0.6, 0.65, 0.7, 0.8, 0.9, 0.95, 0.98, 1.02, 1.05, 1.08, 1.09, 1.0, 1.1, 1.11, 1.12, 1.2, 1.3, 1.4, 1.45, 1.5, 1.55, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.25, 2.3, 2.31, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3.0.

[0070] Aspect 19. The crystalline form of Aspect 14, wherein the crystalline form is a free base and the crystalline form is of formula Va

[0071]

[0072] wherein [solvent] and t are as defined in aspect 14;

[0073] Preferably, the crystalline form is of formula Vb, Vc, Vd, Ve or Vf:

[0074]

[0075]

[0076] wherein t is as defined in aspect 14 or 18;

[0077] Preferably, t is about 0, 0.1, 0.14, 0.17, 0.2, 0.25, 0.3, 0.4, 0.45, 0.5, 0.50, 0.55, 0.57, 0.6, 0.65, 0.7, 0.8, 0.9, 0.95, 0.98, 1.02, 1.05, 1.08, 1.09, 1.0, 1.1, 1.11, 1.12, 1.2, 1.3, 1.4, 1.45, 1.5, 1.55, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.25, 2.3, 2.31, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3.0.

[0078] Aspect 20. The crystalline form according to aspect 19, which is selected from

[0079] Form A free form is characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 9.10±0.2, 9.84±0.2, 10.61±0.2, 11.28±0.2, 12.87±0.2, 13.60±0.2, 14.65±0.2, 0.2, 15.26±0.2, 15.93±0.2, 17.74±0.2, 18.41±0.2, 18.67±0.2, 19.12±0.2, 19.92±0.2, 21.30±0.2, 21.79±0.2, 22.85±0.2, 24.47±0.2, 26.01±0.2, 26.86±0.2, and 37.67±0.2 degrees; or

[0080] The E-type free form is characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 6.64±0.2, 8.65±0.2, 10.06±0.2, 10.94±0.2, 12.86±0.2, 13.84±0.2, 15.75±0.2, 1 6.40±0.2, 17.30±0.2, 18.00±0.2, 19.88±0.2, 20.44±0.2, 21.25±0.2, 21.94±0.2, 23.02±0.2, 23.38±0.2, 23.99±0.2, 25.14±0.2, 26.09±0.2, 26.73±0.2, 26.98±0.2, and 28.43±0.2 degrees; or

[0081] Form F free form is characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 6.65±0.2, 7.14±0.2, 8.45±0.2, 10.88±0.2, 13.29±0.2, 13.46±0.2, 13.92±0.2, 14.46±0.2, 16.63±0.2, 16.96±0.2, 17.23±0.2 or 0.2, 17.57±0.2, 18.06±0.2, 18.98±0.2, 19.48±0.2, 19.66±0.2, 20.84±0.2, 21.66±0.2, 22.98±0.2, 23.33±0.2, 24.09±0.2, 24.35±0.2, 24.85±0.2, 25.53±0.2, 26.09±0.2, 26.72±0.2, 27.81±0.2, 28.31±0.2, and 28.79±0.2 degrees;

[0082] Form I free form is characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of 5.84±0.2, 7.61±0.2, 9.11±0.2, 11.66±0.2, 13.61±0.2, 14.04±0.2, 14.35±0.2, 15.17±0.2, 15.85±0.2, 16.56±0.2, or 0.2, 17.35±0.2, 17.76±0.2, 18.30±0.2, 18.73±0.2, 19.23±0.2, 20.15±0.2, 20.67±0.2, 21.01±0.2, 21.58±0.2, 22.34±0.2, 23.79±0.2, 24.16±0.2, 24.90±0.2, 25.64±0.2, 26.06±0.2, 26.80±0.2, and 27.78±0.2 degrees;

[0083] Type N free form characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of 7.18±0.2, 7.78±0.2, 9.37±0.2, 14.38±0.2, 14.80±0.2, 15.47±0.2 and 21.64±0.2 degrees; or

[0084] The free form of Form W is characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 6.62±0.2, 8.46±0.2, 11.11±0.2, 12.20±0.2, 13.24±0.2, 13.75±0.2, 14.26±0.2, 15.17±0.2, 15.42±0.2, 15.99±0.2, 16.43±0.2, 17. or 7.05±0.2, 17.63±0.2, 17.83±0.2, 19.30±0.2, 19.76±0.2, 20.10±0.2, 21.12±0.2, 22.40±0.2, 23.22±0.2, 23.78±0.2, 24.10±0.2, 24.39±0.2, 25.25±0.2, 25.89±0.2, 27.04±0.2, 27.37±0.2, 28.29±0.2, 28.80±0.2, and 29.41±0.2 degrees;

[0085] Form Z free form is characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of 7.20±0.2, 10.06±0.2, 11.59±0.2, 13.72±0.2, 14.49±0.2, 15.85±0.2, 16.06±0.2, 17.38±0.2, 18.04±0.2, 19.60±0.2, 20.76±0.2, 21.56±0.2, 22.98±0.2, 23.49±0.2, 24.51±0.2, and 28.40±0.2 degrees.

[0086] Aspect 21. The crystalline form according to aspect 19, which is selected from

[0087] Form A free form, characterized by a powder X-ray diffraction pattern comprising diffraction peaks having 2θ angle values ​​of 5.33±0.2, 10.61±0.2, and 12.87±0.2 degrees; preferably having 2θ angle values ​​of 5.33±0.2, 10.61±0.2, 12.87±0.2, 15.93±0.2, and 26.01±0.2 degrees; more preferably having 2θ angle values ​​of 5.33±0.2, 10.61±0.2, 12.87±0.2, 15.93±0.2, 19.12±0.2, 21.79±0.2, and 26.01±0.2 degrees; even more preferably having having 2θ angle values ​​of 5.33±0.2, 10.61±0.2, 12.87±0.2, 15.93±0.2, 18.41±0.2, 19.12±0.2, 21.30±0.2, 21.79±0.2, and 26.01±0.2 degrees; even more preferably having 2θ angle values ​​of 5.33±0.2, 10.61±0.2, 12.87±0.2, 15.26±0.2, 15.93±0.2, 18.41±0.2, 18.67±0.2, 19.12±0.2, 21.30±0.2, 21.79±0.2, and 26.01±0.2 degrees; or

[0088] Form F free form is characterized by a powder X-ray diffraction pattern comprising diffraction peaks having 2θ angle values ​​of 7.14±0.2, 8.45±0.2, and 24.35±0.2 degrees; preferably having 2θ angle values ​​of 7.14±0.2, 8.45±0.2, 13.29±0.2, 16.63±0.2, and 24.35±0.2 degrees; more preferably having 2θ angle values ​​of 7.14±0.2, 8.45±0.2, 13.29±0.2, 16.63±0.2, 16.96±0.2, 22.98±0.2, and 24.35±0.2 degrees; even more preferably having having 2θ values ​​of 7.14±0.2, 8.45±0.2, 13.29±0.2, 13.46±0.2, 13.92±0.2, 16.63±0.2, 16.96±0.2, 22.98±0.2, and 24.35±0.2 degrees; even more preferably having 2θ values ​​of 6.65±0.2, 7.14±0.2, 8.45±0.2, 13.29±0.2, 13.46±0.2, 13.92±0.2, 16.63±0.2, 16.96±0.2, 22.98±0.2, 24.35±0.2, and 26.09±0.2 degrees; or

[0089] Form I free form is characterized by a powder X-ray diffraction pattern comprising diffraction peaks having 2θ angle values ​​of 5.84±0.2, 16.56±0.2, and 25.64±0.2 degrees; preferably having 2θ angle values ​​of 5.84±0.2, 14.04±0.2, 14.35±0.2, 16.56±0.2, and 25.64±0.2 degrees; more preferably having 2θ angle values ​​of 5.84±0.2, 14.04±0.2, 14.35±0.2, 15.85±0.2, 16.56±0.2, 25.64±0.2, and 26.06±0.2 degrees; even more preferably and 15.17 ± 0.2 degrees.

[0090] Aspect 22. The crystalline form of Aspect 14, wherein the crystalline form is of Formula VIa

[0091]

[0092] wherein [solvent], s and t are as defined in aspect 14;

[0093] Preferably, the crystalline form is of formula VIb, VIc, VId, VIe, VIf or VIg,

[0094]

[0095]

[0096] Where s is about 0.3, 0.33, 0.40, 0.44, 0.45, 0.50, 0.55, 0.56, 0.60, 0.63, 0.65, 0.66, 0.67, 0.70, 0.75, 0.76, 0.80, 0.85, 0.90, 0.95, 0.96, 0.97, 0.98, 0.99, 1.0、1.01、1.02、1.03、1.04、1.05、1.06、1.07、1.08、1.09、1.1、1.11、1.12、1.13、1.14、1.15、1.16、1.17、1.18、1.19、1.20、1.3、1.4、1.45、1.5、1.55、 t is about 0, 0.1, 0.14, 0.17, 0.2, 0.25, 0.3, 0.4, 0.45, 0.5, 0.50, 0.55, 0.57, 0.6, 0.65, 0.7, 0.8, 0.9, 0.95, 0.98, 1.02, 1.05, 1.08, 1.09, 1.0, 1.1, 1.11, 1.12, 1.2, 1.3, 1.4, 1.45, 1.5, 1.55, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.25, 2.3, 2.31, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3.0.

[0097] Aspect 23. The crystalline form according to aspect 22, which is selected from

[0098] A citrate salt form, characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 4.95±0.2, 6.59±0.2, 9.03±0.2, 9.98±0.2, 10.84±0.2, 13.02±0.2, 13.23±0.2, 14.56±0.2, 14.96±0.2, 15.55±0.2, 15.94±0.2, 16. .71±0.2, 17.56±0.2, 19.22±0.2, 20.09±0.2, 20.60±0.2, 21.59±0.2, 21.96±0.2, 22.33±0.2, 22.52±0.2, 23.26±0.2, 24.17±0.2, 24.41±0.2, 25.11±0.2, 26.08±0.2, 26.88±0.2, 27.43±0.2, 27.92±0.2, 30.09±0.2, and 30.75±0.2 degrees; or

[0099] Form B citrate salt characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of 6.58±0.2, 8.09±0.2, 9.94±0.2, 10.91±0.2, 13.42±0.2, 14.24±0.2, 14.82±0.2, 16.21±0.2, 18.09±0.2, 18.69±0.2, 19.86±0.2, 20.30±0.2, 20.60±0.2, 21.50±0.2, 22.20±0.2, and 22.99±0.2 degrees; or

[0100] Citrate Form C characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of 4.26±0.2, 5.40±0.2, 6.02±0.2, 6.61±0.2, 8.47±0.2, 10.80±0.2, 12.05±0.2, 12.70±0.2, 15.52±0.2, 16.96±0.2, 19.55±0.2, and 21.24±0.2 degrees; or

[0101] Form E citrate, characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 6.75±0.2, 8.67±0.2, 9.16±0.2, 13.49±0.2, 13.73±0.2, 14.95±0.2, 16.09±0.2, 17.54±0.2, 18.42±0.2, 0.2, 18.61±0.2, 20.25±0.2, 20.64±0.2, 21.66±0.2, 22.61±0.2, 22.92±0.2, 23.58±0.2, 23.92±0.2, 25.06±0.2, 25.59±0.2, 26.11±0.2, 27.24±0.2, 28.82±0.2, 29.75±0.2, 32.31±0.2, and 33.75±0.2 degrees; or

[0102] Form F citrate salt characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of 4.95±0.2, 7.24±0.2, 9.14±0.2, 9.82±0.2, 13.42±0.2, 14.05±0.2, 14.57±0.2, 14.89±0.2, 15.63±0.2, 17.10±0.2, 20.19±0.2, 21.08±0.2 and 21.92±0.2 degrees.

[0103] Aspect 24. The crystalline form according to aspect 22, which is selected from

[0104] A citrate salt, characterized by a powder X-ray diffraction pattern comprising diffraction peaks having 2θ angle values ​​of 14.96±0.2, 17.56±0.2, and 26.08±0.2 degrees; preferably having 2θ angle values ​​of 14.96±0.2, 17.56±0.2, 22.33±0.2, 22.52±0.2, and 26.08±0.2 degrees; more preferably having 2θ angle values ​​of 9.03±0.2, 14.96±0.2, 15.55±0.2, 17.56±0.2, 22.33±0.2, 22.52±0.2, and 26.08±0.2 degrees; even more preferably having 2θ angle values ​​of 9.03±0.2, 10.84±0.2, 14.96±0.2, 15.55±0.2, 17.56±0.2, 20.60±0.2, 22.33±0.2, 22.52±0.2 and 26.08±0.2 degrees; even more preferably having 2θ angle values ​​of 9.03±0.2, 9.98±0.2, 10.84±0.2, 14.96±0.2, 15.55±0.2, 17.56±0.2, 20.60±0.2, 22.33±0.2, 22.52±0.2, 23.26±0.2 and 26.08±0.2 degrees; or

[0105] Form B citrate salt characterized by a powder X-ray diffraction pattern comprising diffraction peaks having 2θ angle values ​​of 6.58±0.2, 13.42±0.2, and 14.82±0.2 degrees; preferably having 2θ angle values ​​of 6.58±0.2, 13.42±0.2, 14.24±0.2, 14.82±0.2, and 19.86±0.2 degrees; more preferably having 2θ angle values ​​of 6.58±0.2, 13.42±0.2, 14.24±0.2, 14.82±0.2, 16.21±0.2, 19.86±0.2, and 20.30±0.2 degrees; even more preferably having 2θ values ​​of 6.58±0.2, 8.09±0.2, 13.42±0.2, 14.24±0.2, 14.82±0.2, 16.21±0.2, 19.86±0.2, 20.30±0.2, and 20.60±0.2 degrees; even more preferably having 2θ values ​​of 6.58±0.2, 8.09±0.2, 9.94±0.2, 13.42±0.2, 14.24±0.2, 14.82±0.2, 16.21±0.2, 18.09±0.2, 19.86±0.2, 20.30±0.2, and 20.60±0.2 degrees; or

[0106] Citrate salt form, characterized by a powder X-ray diffraction pattern comprising diffraction peaks having 2θ angle values ​​of 4.26±0.2, 8.47±0.2, and 12.70±0.2 degrees; preferably having 2θ angle values ​​of 4.26±0.2, 5.40±0.2, 8.47±0.2, 12.70±0.2, and 21.24±0.2 degrees; more preferably having 2θ angle values ​​of 4.26±0.2, 5.40±0.2, 8.47±0.2, 10.80±0.2, 12.70±0.2, 21.24±0.2, and 19.55±0.2 degrees; even more preferably having having 2θ angle values ​​of 4.26±0.2, 5.40±0.2, 6.02±0.2, 8.47±0.2, 10.80±0.2, 12.70±0.2, 15.52±0.2, 16.96±0.2, 19.55±0.2, and 21.24±0.2 degrees; even more preferably having 2θ angle values ​​of 4.26±0.2, 5.40±0.2, 6.02±0.2, 8.47±0.2, 10.80±0.2, 12.70±0.2, 15.52±0.2, 16.96±0.2, 19.55±0.2, 19.91±0.2, and 21.24±0.2 degrees; or

[0107] Form E citrate, characterized by a powder X-ray diffraction pattern comprising diffraction peaks having 2θ angle values ​​of 9.16±0.2, 13.49±0.2, and 13.73±0.2 degrees; preferably having 2θ angle values ​​of 9.16±0.2, 13.49±0.2, 13.73±0.2, 14.95±0.2, and 22.92±0.2 degrees; more preferably having 2θ angle values ​​of 9.16±0.2, 13.49±0.2, 13.73±0.2, 14.95±0.2, 18.42±0.2, 22.92±0.2, and 27.24±0.2 degrees; even more preferably having 2θ angle values ​​of 8.67±0.2, 9.16±0.2, 13.49±0.2, 13.73±0.2, 14.95±0.2, 18.42±0.2, 22.61±0.2, 22.92±0.2, and 27.24±0.2 degrees; even more preferably having 2θ angle values ​​of 8.67±0.2, 9.16±0.2, 13.49±0.2, 13.73±0.2, 14.95±0.2, 18.42±0.2, 21.66±0.2, 22.61±0.2, 22.92±0.2, 25.06±0.2, and 27.24±0.2 degrees; or

[0108] Form F citrate salt characterized by a powder X-ray diffraction pattern comprising diffraction peaks having 2θ angle values ​​of 13.42±0.2, 14.05±0.2, and 20.19±0.2 degrees; preferably having 2θ angle values ​​of 7.24±0.2, 13.42±0.2, 14.05±0.2, 20.19±0.2, and 21.08±0.2 degrees; more preferably having 2θ angle values ​​of 7.24±0.2, 13.42±0.2, 14.05±0.2, 14.57±0.2, 17.10±0.2, 20.19±0.2, and 21.08±0.2 degrees; even more preferably having 2θ angle values ​​of 7.24±0.2, 13.42±0.2, 14.05±0.2, 14.57±0.2, 17.10±0.2, 20.19±0.2, and 21.08±0.2 degrees; Preferably, it has a 2θ angle value of 7.24±0.2, 9.82±0.2, 13.42±0.2, 14.05±0.2, 14.57±0.2, 14.89±0.2, 17.10±0.2, 20.19±0.2 and 21.08±0.2 degrees; even more preferably, it has a 2θ angle value of 4.95±0.2, 7.24±0.2, 9.82±0.2, 13.42±0.2, 14.05±0.2, 14.57±0.2, 14.89±0.2, 17.10±0.2, 20.19±0.2, 21.08±0.2 and 21.92±0.2 degrees.

[0109] Aspect 25. The crystalline form according to aspect 14, which is selected from

[0110] Form A of the L-malate salt is characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 5.06±0.2, ±0.2, 6.97±0.2, 7.28±0.2, 10.09±0.2, 10.49±0.2, 13.36±0.2, 14.67±0.2, 15.13±0.2, 16.08±0.2, 17.02±0.2, 18. or 10±0.2, 18.44±0.2, 18.74±0.2, 19.54±0.2, 20.05±0.2, 20.41±0.2, 21.07±0.2, 22.35±0.2, 22.82±0.2, 23.45±0.2, 23.83±0.2, 25.36±0.2, 25.72±0.2, 28.14±0.2, 29.55±0.2, 30.57±0.2, 31.22±0.2, 32.36±0.2, and 33.38±0.2 degrees;

[0111] Form B succinate, characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 6.79±0.2, 9.13±0.2, 9.40±0.2, 10.22±0.2, 10.81±0.2, 12.09±0.2, 13.53±0.2, 14.25±0.2, 14.86±0.2, 15.25±0.2, 15.90±0.2, 16.55±0.2, 16.81±0.2, 1 or 7.66±0.2, 18.15±0.2, 19.06±0.2, 19.74±0.2, 20.03±0.2, 20.42±0.2, 20.71±0.2, 21.03±0.2, 22.34±0.2, 22.85±0.2, 23.22±0.2, 23.87±0.2, 24.42±0.2, 24.87±0.2, 25.19±0.2, 26.38±0.2, 26.90±0.2, 27.78±0.2, 28.13±0.2, 28.84±0.2, and 29.93±0.2 degrees;

[0112] Form B fumarate salt characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 4.83±0.2, 6.66±0.2, 8.44±0.2, 9.22±0.2, 10.69±0.2, 11.60±0.2, 12.06±0.2, 12.80±0.2, 13.44±0.2, 13.86±0.2, 14.29±0.2, 15.44±0.2, 16.02±0.2, 16.33±0.2 .2, 16.95±0.2, 17.54±0.2, 18.18±0.2, 18.46±0.2, 18.97±0.2, 19.75±0.2, 20.03±0.2, 20.57±0.2, 21.14±0.2, 21.48±0.2, 22.30±0.2, 23.15±0.2, 23.96±0.2, 24.67±0.2, 24.98±0.2, 26.91±0.2, 27.85±0.2, 28.46±0.2, 31.01±0.2, 31.45±0.2, and 35.59±0.2 degrees; or

[0113] D-type fumarate salt, characterized by the following powder X-ray diffraction pattern, which powder X-ray diffraction pattern comprises three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 3.29±0.2, 4.87±0.2, 6.71±0.2, 7.47±0.2, 8.08±0.2, 8.68±0.2, 10.08±0.2, 10.35±0.2, 12.67±0.2, 13.48±0.2, 14.01±0.2, 14.30±0.2, 14.83±0.2. 2, 15.28±0.2, 15.55±0.2, 16.67±0.2, 17.31±0.2, 18.66±0.2, 18.95±0.2, 19.94±0.2, 20.05±0.2, 20.40±0.2, 21.28±0.2, 22.00±0.2, 23.10±0.2, 23.34±0.2, 24.18±0.2, 25.13±0.2, 25.83±0.2, 26.86±0.2, 30.52±0.2, 35.12±0.2, and 35.47±0.2 degrees; or

[0114] A maleate salt form, characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 5.07±0.2, 8.06±0.2, 8.81±0.2, 11.70±0.2, 12.71±0.2, 13.44±0.2, 14.77±0.2, 15.25±0.2, 15.51±0.2, 16.18±0.2, 16.44±0.2, 17.32±0.2, or 0.2, 17.56±0.2, 19.02±0.2, 19.43±0.2, 20.92±0.2, 21.38±0.2, 22.20±0.2, 22.69±0.2, 23.48±0.2, 24.03±0.2, 24.80±0.2, 25.23±0.2, 25.99±0.2, 26.91±0.2, 27.37±0.2, 27.99±0.2, 29.49±0.2, 31.39±0.2, 32.33±0.2, and 33.13±0.2 degrees;

[0115] A hydrochloride salt form, characterized by the following powder X-ray diffraction pattern, which powder X-ray diffraction pattern comprises three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 5.55±0.2, 8.12±0.2, 8.41±0.2, 9.29±0.2, 11.83±0.2, 12.08±0.2, 13.47±0.2, 15.42±0.2, 15.75±0.2, 16.16±0.2, 16.53±0.2, 16. .94±0.2, 18.00±0.2, 18.60±0.2, 19.84±0.2, 20.24±0.2, 21.72±0.2, 22.13±0.2, 23.08±0.2, 23.55±0.2, 24.44±0.2, 26.15±0.2, 26.38±0.2, 26.91±0.2, 27.92±0.2, 28.32±0.2, 33.12±0.2, 33.27±0.2, 34.17±0.2, and 35.28±0.2 degrees; or

[0116] Form C hydrochloride is characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 6.07±0.2, 6.81±0.2, 8.31±0.2, 9.80±0.2, 12.08±0.2, 12.85±0.2, 13.17±0.2, 13.55±0.2, 13.89±0.2, 15.71±0.2, 16.11±0.2, 16.68±0.2, 18.12±0.2, 18.72±0.2 .2, 19.34±0.2, 20.31±0.2, 20.86±0.2, 22.17±0.2, 23.89±0.2, 25.07±0.2, 25.44±0.2, 26.05±0.2, 26.46±0.2, 27.12±0.2, 27.48±0.2, 28.06±0.2, 28.77±0.2, 29.13±0.2, 29.79±0.2, 30.40±0.2, 30.71±0.2, 31.97±0.2, 33.75±0.2, 35.28±0.2, and 35.74±0.2 degrees; or

[0117] A sulfate salt type A, characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 5.19±0.2, 6.87±0.2, 7.71±0.2, 10.28±0.2, 11.14±0.2, 13.59±0.2, 14.63±0.2, 15.35±0.2, 1 5.71±0.2, 16.17±0.2, 18.00±0.2, 18.24±0.2, 19.20±0.2, 20.23±0.2, 20.52±0.2, 21.30±0.2, 22.00±0.2, 22.30±0.2, 22.90±0.2, 24.94±0.2, 25.79±0.2, 28.52±0.2, 29.15±0.2 and 29.55±0.2 degrees.

[0118] Aspect 26. The crystalline form of any of Aspects 14-25, characterized essentially by a powder X-ray diffraction pattern selected from the group consisting of: Figure 1A , Figure 2A , Figure 3A , Figure 4A , Figure 5A , Fig. 7A , Fig. 8A , Fig. 9A , Fig. 10A , Fig.11A , Fig. 12A , Fig.13A , Fig.14A , Fig.15A , Fig.16A , Fig.17A , Fig.18A , Fig.19A or Fig. 20A .

[0119] Aspect 27. A pharmaceutical composition comprising a therapeutically effective amount of the crystalline form according to any one of aspects 14 to 26, and optionally one or more pharmaceutically acceptable carriers.

[0120] Aspect 28. A method for treating or preventing a disorder or disease selected from an inflammatory disorder, an autoimmune disease, or cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of the crystalline form of any one of Aspects 14-26, or the pharmaceutical composition of Aspect 27. BRIEF DESCRIPTION OF THE DRAWINGS

[0121] Figure 1A XRPD pattern of free form A of compound A

[0122] Figure 1BTGA / DSC curve of free form A of compound A

[0123] Figure 1C 1H NMR spectrum of free form of compound A

[0124] Figure 1D DVS diagram of free form A of compound A

[0125] Figure 2A XRPD overlap of free form F of compound A

[0126] Figure 2B TGA / DSC curve of free form F of compound A

[0127] Figure 3A XRPD pattern of free form I of compound A

[0128] Figure 3B TGA / DSC curve of free form I of compound A

[0129] Figure 4A XRPD overlap of the N-type free form of compound A

[0130] Figure 5A VT-XRPD overlap of N- and Z-free forms

[0131] Fig. 6A XRPD overlap of free form E of compound A

[0132] Fig. 7A VT-XRPD overlap of free forms E and W of compound A Fig. 8A XRPD pattern of Form A L-malate of Compound A

[0133] Figure 8B DSC thermogram of L-malate salt of compound A

[0134] Figure 8C TGA thermogram of L-malate salt of compound A

[0135] Fig.8D 1H-NMR spectrum of L-malate salt of compound A

[0136] Fig. 9A XRPD pattern of citrate type A of compound A

[0137] Fig. 9B DSC thermogram of citrate type A of compound A

[0138] Fig. 9C TGA thermogram of compound A citrate type A

[0139] Fig.9D 1H-NMR spectrum of citrate type A of compound A

[0140] Fig.9E DVS isotherm of compound A citrate type A at 25°C Fig. 10A XRPD pattern of Form B fumarate of compound A

[0141] Fig. 10B 1H-NMR spectrum of the B-type fumarate of compound A

[0142] Fig.11A XRPD pattern of D-fumarate salt of compound A

[0143] Fig. 11B DSC thermogram of D-fumarate salt of compound A

[0144] Fig. 11C TGA thermogram of D-fumarate salt of compound A

[0145] Fig.11D 1H-NMR spectrum of D-fumarate salt of compound A

[0146] Fig. 12A XRPD pattern of maleate type A of compound A

[0147] Fig. 12B 1H-NMR spectrum of maleate type A of compound A

[0148] Fig.13A XRPD pattern of Form B succinate of Compound A

[0149] Fig. 13B 1H-NMR spectrum of succinate type A of compound A

[0150] Fig.14A XRPD pattern of Type A hydrochloride of Compound A

[0151] Fig. 14B 1H-NMR spectrum of Compound A hydrochloride type A

[0152] Fig.15A XRPD pattern of Type C hydrochloride of Compound A

[0153] Fig. 15B DSC thermogram of type C hydrochloride of compound A

[0154] Fig. 15C TGA thermogram of Type C hydrochloride of Compound A

[0155] Fig.15D 1H-NMR spectrum of the hydrochloride type C of compound A

[0156] Fig.16A XRPD pattern of compound A sulfate type A

[0157] Fig. 16B 1H-NMR spectrum of compound A sulfate type A

[0158] Fig.17A XRPD pattern of Form B citrate of Compound A

[0159] Fig. 17B DSC thermogram of the B-type citrate salt of compound A

[0160] Fig. 17C TGA thermogram of the B-type citrate salt of compound A

[0161] Fig.17D 1H-NMR spectrum of the B-type citrate of compound A

[0162] Fig.18A XRPD pattern of C-type citrate of compound A

[0163] Fig.18B 1H-NMR spectrum of C-type citrate of compound A

[0164] Fig.19A XRPD pattern of the E-type citrate salt of compound A

[0165] Fig.19B 1H-NMR spectrum of E-citrate salt of compound A

[0166] Fig. 20A XRPD pattern of Form F citrate of Compound A

[0167] Fig. 20B 1H-NMR spectrum of F-type citrate of compound A DETAILED DESCRIPTION

[0168] Although the free base can theoretically form pharmaceutically acceptable salts with many acids, it has been found that the compound A disclosed herein in a specific free base cannot form salts with some acids (such as L-aspartic acid) or cannot form crystalline salts with desired crystallinity. The inventors surprisingly found that the citrate salt of compound A has good crystallinity, safety and production compatibility.

[0169] For the crystalline forms described above, only the main peaks (i.e., the most characteristic, significant, unique and / or reproducible peaks) are summarized; additional peaks can be obtained from the diffraction spectrum by conventional methods. The main peaks described above can be reproduced within the error range (+ or -2 on the last given decimal place, or + or -0.2 on the specified value).

[0170] A method for preparing the free base of compound A is disclosed in WO 2021000925 A1. For the above-mentioned crystalline form, the crystallization step can be carried out in a suitable solvent system containing at least one solvent by solvent evaporation, cooling and / or by adding an anti-solvent (a solvent that is less capable of dissolving compound A or a salt thereof, including but not limited to those described herein) to achieve supersaturation in the solvent system.

[0171] Crystallization can be carried out with or without seeds, as described herein.

[0172] In embodiments of this aspect, provided herein is a citrate salt of compound A, preferably in the above-mentioned crystalline form, more preferably in the crystalline form of type A, B, C, E and F, even more preferably in the crystalline form of type A, B and E, and most preferably in the crystalline form of type A.

[0173] In embodiments of this aspect, provided herein is a free form of Compound A, preferably in the above-mentioned crystalline forms, more preferably in the crystalline forms of Types A, E, F, I, N, W and Z, even more preferably in the crystalline forms of Types A, F and I, and most preferably in the crystalline form of Type A.

[0174] Each crystalline form provided by the present invention forms under specific conditions, which depends on specific thermodynamic characteristics and equilibrium characteristics of crystallization process. Therefore, those skilled in the art know that the crystal formed is the result of the kinetic characteristics and thermodynamic characteristics of crystallization process. Under certain conditions (such as in a specific solvent), a specific crystalline form can have a better characteristic than another crystalline form (or in fact have a better characteristic than any other crystalline form).

[0175] In another aspect, provided herein are pharmaceutical compositions, each containing an effective amount of a citrate salt of Compound A, preferably in any of the above-mentioned crystalline forms. The active compound may comprise 1%-99% (by weight), preferably 1%-70% (by weight), or more preferably 1%-50% (by weight), or most preferably 5%-40% (by weight) of the composition.

[0176] In another aspect, provided herein is the use of the above-mentioned salt or crystalline form of Compound A in the manufacture of a medicament for treating cancer associated with HPK1 inhibition.

[0177] Unless otherwise indicated, as used herein, the term "about" means that a number (eg, temperature, pH, volume, etc.) may vary within ±10%, preferably within ±5%.

[0178] Solvates herein are defined as compounds formed by solvation, such as the combination of solvent molecules with molecules or ions of a solute. Known solvent molecules include water, alcohols, and other polar organic solvents. Alcohols include methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, and tert-butanol. Preferred solvents are typically water. Solvate compounds formed by solvation with water are sometimes referred to as hydrates.

[0179] The following synthetic methods, specific examples and efficacy tests further describe certain aspects of the present invention. They should not limit or define the scope of the present invention in any way.

[0180] In some embodiments, the crystalline form has a crystalline purity of at least about 80%, preferably at least about 90%, preferably at least about 95%, preferably about 97%, more preferably about 99% or more, and most preferably about 100%.

[0181] As used herein, the term "crystalline purity" means the percentage of a specific crystalline form of a compound in a sample, which sample may contain an amorphous form of the compound, one or more other crystalline forms of the compound (in addition to the specific crystalline form of the compound), or a mixture thereof. Crystalline purity is determined by X-ray powder diffraction (XRPD), infrared Raman spectroscopy, and other solid-state methods.

[0182] Examples

[0183] The following examples are intended to be illustrative, and although efforts have been made to ensure accuracy with respect to the numbers used (e.g., amounts, temperatures, etc.), some experimental errors and deviations should be considered within the knowledge of those skilled in the art. Unless otherwise stated, temperatures are expressed in degrees Celsius. Reagents were purchased from commercial suppliers such as Sigma-Aldrich, Alfa Aesar, or TCI and were used without further purification unless otherwise stated.

[0184] 1 H NMR spectra were recorded on a Bruker instrument operated at the specified frequency with a preset pulse sequence.

[0185] Perform powder X-ray diffraction (XRPD) analysis using one of the following methods:

[0186] 1) A PANalytical X'Pert3 diffractometer equipped with a copper radiation source was used. The sample was spread in the middle of a zero-background Si holder and rotated during acquisition. The divergence slit was set to 1 / 8° for continuous illumination. The X-ray tube voltage and amperage were set to 45 kV and 40 mA, respectively. The X-ray tube was set to 40.0 degrees in a θ-θ goniometer at a Cu wavelength (Kα1: Kα2: Data were collected at Kα2 / Kα1 intensity ratio: 0.50) using a 2-θ step size of 0.0263 degrees.

[0187] 2) A PANalytical Empyrean diffractometer equipped with a copper radiation source was used. The sample was spread in the middle of a zero-background Si holder and rotated during acquisition. The divergence slit was set to automatic continuous illumination. The X-ray tube voltage and amperage were set to 45 kV and 40 mA, respectively. The X-ray tube was set to 40.0 degrees in a θ-θ goniometer at a Cu wavelength (Kα1: Kα2: Data were collected at Kα2 / Kα1 intensity ratio: 0.50) using a 2-θ step size of 0.0167 degrees.

[0188] 3) A Bruker D8 Advance diffractometer equipped with a copper radiation source was used. The sample was spread in the middle of a zero-background Si holder and rotated during acquisition. The divergence slit was set to 10.0 mm for continuous illumination. The X-ray tube voltage and amperage were set to 40 kV and 40 mA, respectively. The Cu wavelength (Kα: ) Data were collected using a 2-theta step size of 0.02 degrees.

[0189] Perform thermogravimetric (TGA) analysis using one of the following methods:

[0190] 1) Using a TA TGA 5500 thermogravimetric analyzer, the sample was weighed into an open aluminum pan and protected with a nitrogen flow. The sample was heated from ambient temperature to 350°C at a heating rate of 10°C / min.

[0191] 2) Using a TA TGA 5500 thermogravimetric analyzer, the sample was weighed into an open aluminum pan and protected with a nitrogen flow. The sample was heated from ambient temperature to 300°C at a heating rate of 10°C / min.

[0192] Differential scanning calorimetry (DSC) analysis was performed using a TA DSC 2500 differential scanning calorimeter. The sample was weighed into a crimped aluminum pan and protected with a nitrogen flow. The sample was heated from ambient temperature to the target temperature at a heating rate of 10°C / min.

[0193] Perform dynamic vapor sorption (DVS) analysis with SMSDVS Intrinsic using one of the following methods:

[0194] 1) Weigh the sample into a microbalance. Set the relative humidity to 0% (N2 flow is 200 sccm). Equilibrium is assumed to be reached when the weight change of the sample is <0.001 wt% in 10 min or by a maximum equilibration time of 180 min. The relative humidity is then gradually increased in 10% RH increments to 90%, then to 95%, then to 90%, and then to a final 0% RH in 10% RH decreases. Between two equilibration steps, dm / dt is 0.002% / min. In each equilibration step, equilibrium is assumed to be reached when the weight change of the sample is <0.001 wt% in 10 min or by a maximum equilibration time of 180 min.

[0195] 2) Weigh the sample into a microbalance. Set the relative humidity to the nearest tenth of the ambient humidity (N2 flow is 200 sccm). Equilibrium is assumed to be reached when the weight change of the sample is <0.001 wt% in 10 min or by a maximum equilibration time of 180 min. The relative humidity is then gradually increased to 90% in 10% RH increments, then to 95%, then to 90%, then decreased to 0% in 10% RH decreases, then increased to 90% in 10% RH increments, and then increased to a final 95% RH. Between two equilibration steps, dm / dt is 0.002% / min. In each equilibration step, equilibrium is assumed to be reached when the weight change of the sample is <0.001 wt% in 10 min or by a maximum equilibration time of 180 min.

[0196] 3) Weigh the sample into a microbalance. Set the relative humidity to 40% (N2 flow is 200 sccm). Equilibrium is assumed to be reached when the weight change of the sample is <0.001 wt% in 60 min or by a maximum equilibration time of 360 min. The relative humidity is then reduced to 0% in 10% RH decreases, then increased to 90% in 10% RH increments, then to 95%, then to 90%, and then reduced to a final 40% RH in 10% RH decreases. Between two equilibration steps, dm / dt is 0.002% / min. In each equilibration step, equilibrium is assumed to be reached when the weight change of the sample is <0.001 wt% in 60 min or by a maximum equilibration time of 360 min.

[0197] In the following instances, the following abbreviations may be used:

[0198] AcOH Acetic acid ACN or MeCN Acetonitrile AHr Water-based DMF N,N-Dimethylformamide DMSO Dimethyl sulfoxide EtOAc Ethyl acetate EtOH Ethanol <![CDATA[Et2O or ether]]> Diethyl ether g gram h or hr Hour HCl hydrochloric acid HPLC High performance liquid chromatography IPA 2-Propanol i-PrOH Isopropyl alcohol mg mg mL mL mmol mmol MeOH Methanol Min minute PE Petroleum ether RH Relative humidity R Retention time Rt or rt Room temperature TFA Trifluoroacetic acid THF Tetrahydrofuran TLC Thin layer chromatography μL microliter

[0199] Example 1: Preparation and XRPD data of free form Form A of Compound A

[0200] Compound A (110 g, obtained by the same method disclosed in WO 2021000925 A1) was dissolved in refluxing anhydrous EtOH (2000 mL) until all solids were dissolved. The solution was cooled to 10 ° C and stirred for 5 h, when a large amount of solids appeared. The solid was collected by filtration, and the material was recrystallized with anhydrous EtOH (2200 mL). The solid was collected by filtration, and the solid was then dried under vacuum to give Compound A (62 g, 54%) in free form of Type A.

[0201] Table 1: Characteristic XRPD information of Form A free form of Compound A

[0202]

[0203] The solid form stability of the free form of type A in process solvents EtOH / H2O and MeOH / H2O was studied. At 50°C, no form change of type A was observed in MeOH. No form change was observed under laboratory conditions, which indicates that the sample has good physical stability. For HPLC area purity, about 1.2 area % reduction was observed in Vis (10000Lux) for 5 days. The purity change was less than 0.4 area % under all other conditions (40°C / 75%RH / open for 2 weeks, 60°C / sealed for 10 days, RT / 92.5%RH / open for 10 days, 25°C / 60%RH / open for 8 weeks and UV (290μw / cm2) 3 days).

[0204] Example 2: Preparation and XRPD data of free form Form F of Compound A

[0205] In a glass vial, Compound A Form A free form (19.6 mg) was suspended in acetonitrile (0.50 mL). The slurry was stirred using magnetic stirring at 50° C. for 1 week. The resulting solid was isolated to give Compound A Form F free form.

[0206] Table 2: Characteristic XRPD information of Form F free form of Compound A

[0207]

[0208]

[0209] Example 3: Preparation and XRPD data of Form I free form of Compound A

[0210] In a glass vial, Compound A Form A free form (20.2 mg) was suspended in toluene (0.50 mL). The slurry was stirred using magnetic stirring at 50° C. for 1 week. The resulting solid was isolated to give Compound A in Form I free form.

[0211] Table 3: Characteristic XRPD information of Form I free form of Compound A

[0212]

[0213]

[0214] Example 4: Preparation and XRPD data of the N-type free form of Compound A

[0215] In a vial with a perforated cap, Compound A Form A free form (20.9 mg) was dissolved in EtOH / water (1.0 mL, 4:1) to evaporate slowly. After 1 week, the solid was isolated to give Compound A as Form N free form.

[0216] Table 4: Characteristic XRPD information of the N-type free form of Compound A

[0217]

[0218] Example 5: Preparation and XRPD data of the free form of Form Z of Compound A

[0219] Compound A Form Z free form is heated to 100°C under nitrogen to give Compound A in Form Z free form.

[0220] Table 5: Characteristic XRPD information of the Z-free form of Compound A

[0221]

[0222] Example 6: Preparation and XRPD data of free form E of compound A

[0223] In a glass vial, Compound A Form A free form (20.2 mg) was suspended in acetone (0.50 mL). The slurry was stirred using magnetic stirring at 50° C. for 1 week. The resulting solid was isolated to give Compound A Form E free form.

[0224] Table 6: Characteristic XRPD information of Form E free form of Compound A

[0225]

[0226]

[0227] Example 7: Preparation and XRPD data of free form of compound A

[0228] Compound A Form E free form was heated to 100°C under nitrogen to give Compound A Form W free form.

[0229] Table 7: Characteristic XRPD information of Form W free form of Compound A

[0230]

[0231]

[0232] Example 8: Preparation and XRPD data of Form A L-malate salt of Compound A

[0233] In a glass vial, Compound A Form A free form (50 mg) was suspended in ethanol (0.50 mL), followed by the addition of L-malic acid (15 mg). The mixture was stirred at 50 ° C for 2 h using magnetic stirring, and then stirred at 25 ° C for 12 h. The resulting solid was isolated to give Compound A Form A L-malate. The stoichiometric ratio of Compound A to malic acid was 1: 1.

[0234] L-malate Form A is hygroscopic. It absorbs about 7.9% water from 40% RH to 95% RH at 25°C. No form change was observed after DVS testing.

[0235] Form A L-malate is a highly crystalline hemihydrate. DSC T is 80.9°C 起始 The endothermic peak is shown at 190.4 °C, corresponding to dehydration. 起始 Melting peak occurs at 121°C. Decomposition occurs during melting. TGA shows about 1.5% weight loss up to 121°C. No residual solvent is detected. KF analysis shows about 2.7% water by weight (0.67 equivalents in molar ratio). L-malate Form A is chemically and physically stable at 25°C / 92%RH in an open container, at 40°C / 75%RH in an open container, and at 60°C in a closed container for 1 week.

[0236] Table 8: Characteristic XRPD information of Form A L-malate salt of Compound A

[0237]

[0238]

[0239] Example 9: Preparation and XRPD data of Form A citrate salt of Compound A

[0240] In a glass vial, Compound A Form A free form (50 mg) was suspended in ethanol (0.50 mL), followed by the addition of citric acid (22 mg). The mixture was stirred at 50 ° C for 2 h using magnetic stirring, and then at 25 ° C for 12 h. The resulting solid was isolated to give Compound A as Form A citrate. The stoichiometric ratio of Compound A to citric acid was 1:1.

[0241] Type A citrate is a highly crystalline anhydrous salt. DSC T is 212.9℃ 起始 The melting peak is shown at . Decomposition occurs during melting. The TGA curve shows that the weight loss of Type A citrate from 30°C to 100°C is observed to be -0.243%. Type A citrate is chemically and physically stable at 25°C / 92%RH in an open container, at 40°C / 75%RH in an open container, and at 60°C in a closed container for 1 week. Type A citrate is slightly hygroscopic. At 25°C, it absorbs about 0.7% of water from 0%RH to 95%RH. No form change was observed after DVS testing. 1 H NMR (400 MHz, DMSO-d6) δ 12.36 (s, 1H), 8.90 (s, 1H), 8.50–8.43 (m, 1H), 8.24 (s, 1H), 8.22–8.16 (m, 1H), 7.91 (s, 1H), 7.88 (s, 1H), 7.24 (d, J=7.9 Hz, 1H), 4.04 (s, 2H), 3.26–3.15 (m, 2H), 3.15–3.07 (m, 2H), 3.03 (s, 3H), 2.83 (s, 3H), 2.79 (s, 3H), 2.63, 2.56 (AB q, J=15.2 Hz, 4H, citrate), 2.30 (s, 3H), 2.29 (s, 3H).

[0242] Table 9: Characteristic XRPD information of Compound A, Citrate Form A

[0243]

[0244]

[0245] Example 10: Preparation and XRPD data of Form B fumarate salt of Compound A

[0246] In a glass vial, Compound A free form (50 mg) was suspended in acetone (0.50 mL), followed by the addition of fumaric acid (7 mg). The mixture was stirred for 2 h at 50 ° C using magnetic stirring, and then stirred for 12 h at 25 ° C. The resulting solid was separated to give Compound A in Form B fumarate. The stoichiometric ratio of Compound A to fumaric acid was 1:0.5.

[0247] Table 10: Characteristic XRPD information of Form B fumarate salt of Compound A

[0248]

[0249]

[0250] Example 11: Preparation and XRPD data of D-fumarate salt of compound A

[0251] In a glass vial, the free form of compound A (50 mg) was suspended in tetrahydrofuran (0.50 mL), followed by the addition of fumaric acid (13 mg). The mixture was stirred for 2 h at 50 ° C using magnetic stirring, and then stirred for 12 h at 25 ° C. The resulting solid was separated to give compound A in the form of D fumarate. The stoichiometric ratio of compound A to fumaric acid was 1: 1.

[0252] The D-type fumarate of Compound A has medium crystallinity, and the melting onset temperature is 160.5°C.

[0253] Table 11: Characteristic XRPD information of D-fumarate salt of Compound A

[0254]

[0255]

[0256] Example 12: Preparation and XRPD data of maleate salt Form A of Compound A

[0257] In a glass vial, Compound A Form A free form (50 mg) was suspended in acetonitrile (0.50 mL), followed by the addition of maleic acid (13 mg). The mixture was stirred at 50 ° C for 2 h using magnetic stirring, and then stirred at 25 ° C for 12 h. The resulting solid was separated to give Compound A in Form A maleate. The stoichiometric ratio of Compound A to maleic acid was 1: 1.

[0258] Table 12: Characteristic XRPD information of Form A maleate salt of Compound A

[0259]

[0260]

[0261] Example 13: Preparation and XRPD data of Form B succinate salt of Compound A

[0262] In a glass vial, the free form of compound A (50 mg) was suspended in tetrahydrofuran (0.50 mL), followed by the addition of succinic acid (14 mg). The mixture was stirred for 2 h at 50 ° C using magnetic stirring, and then stirred for 12 h at 25 ° C. The resulting solid was separated to give compound A in the form of succinate with high crystallinity. The stoichiometric ratio of compound A to succinic acid was 1: 1.

[0263] Table 13: Characteristic XRPD information of Form B succinate salt of Compound A

[0264]

[0265]

[0266] Example 14: Preparation and XRPD data of Compound A hydrochloride type A

[0267] In a glass vial, the free form of compound A (50 mg) was suspended in tetrahydrofuran (0.50 mL), followed by the addition of hydrochloric acid (115 μL, 1.0 M). The mixture was stirred at 50 ° C for 2 h using magnetic stirring, and then stirred at 25 ° C for 12 h. The resulting solid was separated to give compound A as a hydrochloride salt. The stoichiometric ratio of compound A to hydrogen chloride was 1: 1.

[0268] Table 14: Characteristic XRPD information of Compound A, Form A hydrochloride

[0269]

[0270]

[0271] Example 15: Preparation and XRPD data of Form C hydrochloride of Compound A

[0272] In a glass vial, the free form of compound A (50 mg) was suspended in acetonitrile (0.50 mL), followed by the addition of hydrochloric acid (115 μL, 1.0 M). The mixture was stirred at 50 ° C for 2 h using magnetic stirring, and then stirred at 25 ° C for 12 h. The resulting solid was separated to give compound A as a hydrochloride salt of form C. The stoichiometric ratio of compound A to hydrogen chloride was 1: 1.

[0273] Form C hydrochloride has moderate crystallinity. DSC shows that the dehydration onset temperature is 53.4.

[0274] Table 15: Characteristic XRPD information of Compound A, Form C hydrochloride

[0275]

[0276]

[0277] Example 16: Preparation and XRPD data of Compound A Sulfate Form A

[0278] In a glass vial, the free form of compound A (50 mg) was suspended in acetonitrile (0.50 mL), followed by the addition of sulfuric acid (115 μL, 1.0 M). The mixture was stirred at 50 ° C for 2 h using magnetic stirring, and then stirred at 25 ° C for 12 h. The resulting solid was separated to give compound A as a sulfate salt of type A. The stoichiometric ratio of compound A to sulfuric acid was 1:0.5.

[0279] Table 16: Characteristic XRPD information of Compound A Sulfate Form A

[0280]

[0281] Example 17: Preparation and XRPD data of Form B citrate salt of Compound A

[0282] At 50°C in a glass vial, Compound A Form Citrate (40 mg) was dissolved in a minimum of 2v:1v trifluoroethanol and acetone. The solution was filtered through a 0.45 μm syringe filter. The filtrate was cooled to 5°C at a rate of 0.1°C / min. The resulting solid was separated to give Compound A Form Citrate. The stoichiometric ratio of Compound A to citric acid was 1:1.

[0283] Citrate B is a potential solvate in the TFE channel. It was obtained by slow cooling and fast cooling of TFE / acetone (2:1, v / v), and by slow cooling of TFE / ACN (2:1, v / v). The wet cake of Citrate B has high crystallinity. DSC showed a T of 90.9 °C. 起始 and an endothermic peak with an enthalpy of about 64 J / g, which corresponds to the desolvation of TFE. 起始 Melting peak appears at . Decomposition occurs during melting. There are two weight loss steps in TGA, about 1.9% up to about 92°C and about 8% from 92°C to 164°C. No residual solvent was detected by 1H-NMR after air drying overnight in a fume hood. The stoichiometric ratio of the free form to citric acid is 1:1. KF test shows that it contains about 2.7% water by weight. Under ambient and open conditions (about 25°C and about 80% RH), Form B citrate converts to Form A within 1 week.

[0284] Table 17: Characteristic XRPD information of Form B citrate salt of Compound A

[0285]

[0286] Example 18: Preparation and XRPD data of Form C citrate salt of Compound A

[0287] At 50°C in a glass vial, Compound A Form Citrate (40 mg) was dissolved in a minimum of 2v:1v trifluoroethanol and tetrahydrofuran. The solution was filtered through a 0.45 μm syringe filter. The filtrate was cooled to 5°C at a rate of 0.1°C / min. The resulting solid was separated to give Compound A Form C Citrate. The stoichiometric ratio of Compound A to citric acid was 4:3.

[0288] Table 18: Characteristic XRPD information of Form C citrate salt of Compound A

[0289]

[0290] Example 19: Preparation and XRPD data of Form E citrate salt of Compound A

[0291] At ambient temperature in a glass vial, the A-type citrate of compound A (40 mg) was dissolved in a minimum of 2v:1v trifluoroethanol and acetonitrile. The solution was filtered through a 0.45 μm syringe filter. The filtrate was left in a vial with a perforated cap to evaporate slowly within a week. The resulting solid was separated to give compound A in the E-type citrate. The stoichiometric ratio of compound A to citric acid was 1:1.

[0292] Table 19: Characteristic XRPD information of Form E citrate salt of Compound A

[0293]

[0294]

[0295] Example 20: Preparation and XRPD data of Form F citrate salt of Compound A

[0296] In a glass vial, the A-type citrate of compound A (50 mg) was dissolved in dimethyl sulfoxide (1.0 mL) at ambient temperature. The solution was filtered through a 0.45 μm syringe filter. Water (4 mL) was slowly added to the solution, the resulting solution was thoroughly mixed and then placed at 5 ° C for one week. The resulting solid was separated to give compound A in the F-type citrate. The stoichiometric ratio of compound A to citric acid was 1: 0.56.

[0297] Table 20: Characteristic XRPD information of Form F citrate salt of Compound A

[0298]

[0299] Example 21: Pharmacokinetic study of the amorphous free form of Compound A and the citrate form of Compound A in mice

[0300] The amorphous free form of Compound A (115.7 mg) was prepared by lyophilization of a suspension of the free form of Compound A in water (with a minimal amount of acetonitrile).

[0301] In accordance with the guidelines of the Institutional Animal Care and Use Committee, the pharmacokinetic study of compound A was conducted in male CD-1 mice (Vital River, 8 weeks, 3 animals for each route of administration). Intravenous administration was formulated as a 0.20 mg / mL solution in N, N-dimethylacetamide: 30% solutol HS-15 (w / v): saline = 20:20:60 (V:V:V). Oral administration was formulated as a 1.0 mg / mL suspension in 0.5% methylcellulose. Blood samples were collected within 24 hours after administration. Plasma was separated and processed according to the following scheme: 200 μL of ACN containing 5 ng / mL terfenadine as an internal standard was added to an aliquot of 10 μL plasma. The mixture was vortexed for 1 min and centrifuged at 4000 rpm for 10 min. An aliquot of 50 μL supernatant was diluted with 150 μL acetonitrile / water. The concentration of compound A was determined by LC-MS-MS. Non-compartmental pharmacokinetic analysis was performed on the concentration-time data.

[0302] Table 21: Pharmacokinetic parameters of Compound A in mice

[0303]

[0304]

[0305] Example 22: Pharmacokinetic study of the amorphous free form of Compound A and the citrate form of Compound A in rats

[0306] In accordance with the guidelines of the Institutional Animal Care and Use Committee, the pharmacokinetic study of compound A was conducted in male SD rats (Weitong Lihua Company, 8 weeks, 3 animals for each route of administration). Intravenous administration was formulated as a 1.0 mg / mL solution in N, N-dimethylacetamide: 30% solutol HS-15 (w / v): saline = 20:20:60 (V:V:V). Oral administration was formulated as a 1.0 mg / mL suspension in 0.5% methylcellulose. Blood samples were collected within 24 hours after administration. Plasma was separated and processed according to the following scheme: 200 μL of ACN containing 5 ng / mL terfenadine as an internal standard was added to aliquots of 10 μL plasma. The mixture was vortexed for 1 min and centrifuged at 4000 rpm for 10 min. An aliquot of 50 μL supernatant was diluted with 150 μL acetonitrile / water. The concentration of compound A was determined by LC-MS-MS. Non-compartmental pharmacokinetic analysis was performed on the concentration-time data.

[0307] Table 22: Pharmacokinetic parameters of Compound A in rats

[0308]

[0309]

[0310] The foregoing examples and descriptions of certain embodiments should be considered illustrative, rather than limiting, of the present invention as defined by the claims. As will be readily appreciated, many variations and combinations of the features set forth above may be used without departing from the present invention as set forth in the claims. All of these variations are intended to be included within the scope of the present invention. All references cited are incorporated herein by reference in their entirety.

[0311] It will be appreciated that, even if any prior art publication is referred to herein, this reference does not constitute an admission that the publication forms part of the common general knowledge in the art in any country.

[0312] In the following claims and the foregoing embodiments of the present invention, unless the context requires otherwise due to expressive language or necessary meaning, the word "comprise" or variations such as "comprises" or "comprising" are used in an inclusive sense, that is, specifying the presence of the features described, but not excluding the presence or addition of other features in various embodiments of the present invention.

[0313] The disclosures of all publications, patents, patent applications, and published patent applications cited herein by identifying citation are incorporated herein by reference in their entirety.

Claims

1. A pharmaceutically acceptable salt of 4-[2-(2,8-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]-N,N,2-trimethylbenzamide, wherein the pharmaceutically acceptable salt is one or more inorganic salts or one or more organic salts.

2. The salt according to claim 1, which is in solid form.

3. The salt of claim 1 or 2, wherein the salt is an inorganic salt selected from the group consisting of hydrochloride, sulfate, phosphate, hydrobromide and / or nitrate; or an organic salt selected from the group consisting of fumarate, tartrate (L-tartrate, D-tartrate or DL-tartrate), laurate, stearate, gentisate, nicotinate, aspartate (L-aspartate), succinate, adipate, malate (L-malate), citrate, maleate, glycolate, gluconate (D-gluconate), lactate (L-lactate), acetate, benzenesulfonate, methanesulfonate, mesylate, benzoate, naphthysulfonate, and / or oxalate; Preferably, the salt is selected from hydrochloride, sulfate, phosphate, hydrobromide, fumarate, tartrate (L-tartrate, D-tartrate or DL-tartrate), aspartate (L-aspartate), succinate, malate (L-malate), citrate, maleate, methanesulfonate or mesylate; More preferably, the salt is selected from L-malate, citrate or succinate; Even more preferably, the salt is citrate.

4. The salt of claim 3, wherein the salt is a compound having formula (I): wherein n is a number from about 0.2 to about 2.

0.

5. The salt of claim 4, wherein n is a number from about 0.3 to about 1.5; preferably n is a number selected from the group consisting of: 0.3±0.1, 0.5±0.1, 0.7±0.1, 1.0±0.1 and 1.5±0.1; Preferably, n is a number selected from the group consisting of 0.3±0.05, 0.5±0.05, 0.6±0.05, 0.7±0.05, 0.8±0.05, 1.0±0.05, 1.1±0.05 and 1.5±0.05; More preferably, n is 0.25-0.35, 0.55-0.65, 0.65-0.75, 0.75-0.85, 0.85-0.95, 0.95-1.05, 1.05-1.15 or 1.45-1.55; Even more preferably, n is about 0.3, 0.33, 0.40, 0.44, 0.45, 0.50, 0.55, 0.56, 0.60, 0.63, 0.65, 0.66, 0.67, 0.70, 0.75, 0.76, 0.80, 0.85, 0.90, 0.95, 0.96, 0.97, 0.98, 0.99, 1.0, 1.01, 1.02, 1.03, 1.04, 1.05, 1.06, 1.1, 1.45, 1.5, 1.55, 1.67, 1.8, 1.90, 1.95, 2.

0.

6. The salt of claim 3, wherein the salt is L-malate.

7. The salt of claim 6, wherein the salt is a compound having formula (II): wherein m is a number from about 0.5 to about 2.

0.

8. The salt of claim 7, wherein m is a number from about 0.5 to about 1.5; Preferably m is a number selected from the group consisting of 0.5±0.1, 0.7±0.1, 1.0±0.1 and 1.5±0.1; More preferably, m is a number selected from the group consisting of 0.5±0.05, 0.6±0.05, 0.7±0.05, 0.8±0.05, 0.9±0.05, 1.0±0.05, 1.1±0.05, 1.2±0.05 and 1.5±0.05; Even more preferably, m is 0.95-1.05, 1.05-1.15, 1.15-1.25 or 1.45-1.55; Even more preferably, m is about 0.45, 0.50, 0.55, 0.95, 0.98, 0.99, 1.0, 1.01, 1.02, 1.05, 1.06, 1.07, 1.08, 1.09, 1.10, 1.11, 1.12, 1.13, 1.14, 1.15, 1.16, 1.17, 1.18, 1.19, 1.20, 1.3, 1.4, 1.45 or 1.

5.

9. The salt of claim 3, wherein the salt is succinate.

10. The salt of claim 9, wherein the salt is a compound having formula (III): wherein r is a number from about 0.2 to about 2.

0.

11. The salt of claim 10, wherein r is a number from about 0.5 to about 1.5; Preferably r is a number selected from the group consisting of: 0.5±0.1, 0.7±0.1, 1.0±0.1 and 1.5±0.1; More preferably, r is a number selected from the group consisting of 0.5±0.05, 0.6±0.05, 0.7±0.05, 0.8±0.05, 0.9±0.05, 1.0±0.05, 1.1±0.05, 1.2±0.05 and 1.5±0.05; Even more preferably, r is 0.95-1.05, 1.05-1.15, 1.15-1.25 or 1.45-1.55; Even more preferably, r is 0.45, 0.50, 0.55, 0.95, 0.98, 0.99, 1.0, 1.01, 1.02, 1.05, 1.06, 1.07, 1.08, 1.09, 1.10, 1.11, 1.12, 1.13, 1.14, 1.15, 1.16, 1.17, 1.18, 1.19, 1.20, 1.3, 1.4, 1.45 or 1.

5.

12. A pharmaceutical composition comprising a therapeutically effective amount of a salt according to any one of claims 1 to 11, and optionally one or more pharmaceutically acceptable carriers.

13. A method for treating or preventing a disorder or disease selected from an inflammatory disorder, an autoimmune disease, or cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a salt according to any one of claims 1 to 11, or a pharmaceutical composition according to claim 12.

14. A crystalline form having formula IV wherein [acid] is selected from the group consisting of organic acids and inorganic acids; [Solvent] is selected from H2O or an organic solvent; s is a number from about 0.0 to about 5.0; t is a number from about 0.0 to about 5.

0.

15. The crystalline form of claim 14, wherein [acid] is selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, nitric acid, fumaric acid, L-tartaric acid, D-tartaric acid, DL-tartaric acid, lauric acid, stearic acid, gentisic acid, nicotinic acid, aspartic acid, succinic acid, adipic acid, malic acid (L-malic acid), citric acid, maleic acid, ascorbic acid (L-ascorbic acid), glycolic acid, gluconic acid (D-gluconic acid), lactic acid (L-lactic acid), acetic acid, benzenesulfonic acid, methanesulfonic acid, benzoic acid, naphthalenesulfonic acid, and / or oxalic acid; Preferably, [acid] is selected from hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, fumaric acid, tartaric acid (L-tartaric acid or D-tartaric acid), aspartic acid (L-aspartic acid), succinic acid, malic acid (L-malic acid), citric acid, maleic acid, methanesulfonic acid; More preferably, [acid] is selected from L-malic acid, citric acid, succinic acid; Even more preferably [the acid] is selected from citric acid.

16. The crystalline form of any one of claims 14-15, wherein s is a number from about 0 to about 1.5; Preferably s is a number selected from the group consisting of 0.3±0.1, 0.5±0.1, 0.7±0.1, 1.0±0.1 and 1.5±0.1; More preferably s is a number selected from the group consisting of 0.3±0.05, 0.5±0.05, 0.6±0.05, 0.7±0.05, 0.8±0.05, 1.0±0.05, 1.1±0.05, 1.2±0.05 and 1.5±0.05; Even more preferably, s is a number selected from the group consisting of 0.25-0.35, 0.55-0.65, 0.65-0.75, 0.75-0.85, 0.85-0.95, 0.95-1.05, 1.05-1.15, 1.15-1.25 or 1.45-1.55; Even more preferably, s is 0.55-0.65, 0.65-0.75, 0.75-0.85, 0.85-0.95, 0.95-1.05, 1.05-1.15 or 1.45-1.55; even more preferably, s is 0.3, 0.33, 0.40, 0.44, 0.45, 0.50, 0.55, 0.56, 0.60, 0.63, 0.65, 0.66, 0.67, 0.70, 0.75, 0.76, 0.80, 0.85, 0. .90, .95, .96, .97, .98, .99, 1.0, 1.01, 1.02, 1.03, 1.04, 1.05, 1.06, 1.07, 1.08, 1.09, 1.1, 1.11, 1.12, 1.13, 1.14, 1.15, 1.16, 1.17, 1.18, 1.19, 1.20, 1.3, 1.4, 1.45, 1.5, 1.55, 1.67, 1.8, 1.90, 1.95, or 2.

0.

17. The crystalline form of claim 14, wherein [Solvent] is selected from the group consisting of an inorganic solvent selected from the group consisting of H2O, MeOH, EtOH, n-PrOH, i-PrOH, 1-butanol, sec-BuOH, tert-BuOH CF3CH2OH, acetone, toluene, THF, MeOAc, EtOAc, PrOAc, dioxane, chloroform, DCM, butanone, and MeCN, or a combination of any of the foregoing inorganic solvents; Preferably, [Solvent] is selected from the group consisting of an inorganic solvent selected from the group consisting of H2O, MeOH, EtOH, n-PrOH, i-PrOH, 1-BuOH, sec-BuOH, tert-BuOH, CF3CH2OH, acetone, toluene, THF, MeOAc, EtOAc, PrOAc, dioxane, chloroform, DCM, butanone, MeCN, (H2O and EtOH), (H2O and acetone) or (H2O and MeCN); Even more preferably, the solvent is selected from H2O, MeOH, EtOH, n-PrOH, i-PrOH, CF3CH2OH or (H2O and EtOH) or (H2O and MeOH) or (H2O and i-PrOH) or (H2O and n-PrOH) or (H2O, n-PrOH and i-PrOH) or any combination thereof.

18. The crystalline form of any one of claims 14 and 17, wherein t is a number from about 0 to about 3; Preferably t is a number selected from the group consisting of: 0, 0.5±0.2, 1.0±0.2, 1.5±0.2, 2.0±0.2, 2.5±0.2, 3.0±0.2; More preferably, t is 0-0.13, 0.13-0.25, 0.25-0.5, 0.5-0.67, 0.67-0.75, 0.75-1, 1-1.5, 1.5-2, 2-2.5, 2.5-3; Even more preferably, t is about 0, 0.1, 0.14, 0.17, 0.2, 0.25, 0.3, 0.4, 0.45, 0.5, 0.50, 0.55, 0.57, 0.6, 0.65, 0.7, 0.8, 0.9, 0.95, 0.98, 1.02, 1.05, 1.08, 1.09, 1.0, 1.1, 1.11, 1.12, 1.2, 1.3, 1.4, 1.45, 1.5, 1.55, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.25, 2.3, 2.31, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3.

0.

19. The crystalline form of claim 14, wherein the crystalline form is a free base and the crystalline form is of formula Va wherein [solvent] and t are as defined in claim 14; Preferably, the crystalline form is of formula Vb, Vc, Vd, Ve or Vf: wherein t is as defined in claim 14 or 18; Preferably, t is about 0, 0.1, 0.14, 0.17, 0.2, 0.25, 0.3, 0.4, 0.45, 0.5, 0.50, 0.55, 0.57, 0.6, 0.65, 0.7, 0.8, 0.9, 0.95, 0.98, 1.02, 1.05, 1.08, 1.09, 1.0, 1.1, 1.11, 1.12, 1.2, 1.3, 1.4, 1.45, 1.5, 1.55, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.25, 2.3, 2.31, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3.

0.

20. The crystalline form of claim 19, selected from A free form, characterized by The powder X-ray diffraction pattern comprises three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 9.10±0.2, 9.84±0.2, 10.61±0.2, 11.28±0.2, 12.87±0.2, 13.60±0.2, 14.65±0.2, 15 .26±0.2, 15.93±0.2, 17.74±0.2, 18.41±0.2, 18.67±0.2, 19.12±0.2, 19.92±0.2, 21.30±0.2, 21.79±0.2, 22.85±0.2, 24.47±0.2, 26.01±0.2, 26.86±0.2, and 37.67±0.2 degrees; or The E-type free form is characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 6.64±0.2, 8.65±0.2, 10.06±0.2, 10.94±0.2, 12.86±0.2, 13.84±0.2, 15.75±0.2, 1 6.40±0.2, 17.30±0.2, 18.00±0.2, 19.88±0.2, 20.44±0.2, 21.25±0.2, 21.94±0.2, 23.02±0.2, 23.38±0.2, 23.99±0.2, 25.14±0.2, 26.09±0.2, 26.73±0.2, 26.98±0.2, and 28.43±0.2 degrees; or Form F free form is characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 6.65±0.2, 7.14±0.2, 8.45±0.2, 10.88±0.2, 13.29±0.2, 13.46±0.2, 13.92±0.2, 14.46±0.2, 16.63±0.2, 16.96±0.2, 17.23±0.2 or 0.2, 17.57±0.2, 18.06±0.2, 18.98±0.2, 19.48±0.2, 19.66±0.2, 20.84±0.2, 21.66±0.2, 22.98±0.2, 23.33±0.2, 24.09±0.2, 24.35±0.2, 24.85±0.2, 25.53±0.2, 26.09±0.2, 26.72±0.2, 27.81±0.2, 28.31±0.2, and 28.79±0.2 degrees; Form I free form is characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of 5.84±0.2, 7.61±0.2, 9.11±0.2, 11.66±0.2, 13.61±0.2, 14.04±0.2, 14.35±0.2, 15.17±0.2, 15.85±0.2, 16.56±0.2, or 0.2, 17.35±0.2, 17.76±0.2, 18.30±0.2, 18.73±0.2, 19.23±0.2, 20.15±0.2, 20.67±0.2, 21.01±0.2, 21.58±0.2, 22.34±0.2, 23.79±0.2, 24.16±0.2, 24.90±0.2, 25.64±0.2, 26.06±0.2, 26.80±0.2, and 27.78±0.2 degrees; Type N free form characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of 7.18±0.2, 7.78±0.2, 9.37±0.2, 14.38±0.2, 14.80±0.2, 15.47±0.2 and 21.64±0.2 degrees; or The free form of Form W is characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 6.62±0.2, 8.46±0.2, 11.11±0.2, 12.20±0.2, 13.24±0.2, 13.75±0.2, 14.26±0.2, 15.17±0.2, 15.42±0.2, 15.99±0.2, 16.43±0.2, 17. or 7.05±0.2, 17.63±0.2, 17.83±0.2, 19.30±0.2, 19.76±0.2, 20.10±0.2, 21.12±0.2, 22.40±0.2, 23.22±0.2, 23.78±0.2, 24.10±0.2, 24.39±0.2, 25.25±0.2, 25.89±0.2, 27.04±0.2, 27.37±0.2, 28.29±0.2, 28.80±0.2, and 29.41±0.2 degrees; Form Z free form is characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of 7.20±0.2, 10.06±0.2, 11.59±0.2, 13.72±0.2, 14.49±0.2, 15.85±0.2, 16.06±0.2, 17.38±0.2, 18.04±0.2, 19.60±0.2, 20.76±0.2, 21.56±0.2, 22.98±0.2, 23.49±0.2, 24.51±0.2, and 28.40±0.2 degrees.

21. The crystalline form of claim 19, selected from A free form, characterized by A powder X-ray diffraction pattern comprising diffraction peaks having 2θ angle values ​​of 5.33±0.2, 10.61±0.2, and 12.87±0.2 degrees; preferably having 2θ angle values ​​of 5.33±0.2, 10.61±0.2, 12.87±0.2, 15.93±0.2, and 26.01±0.2 degrees; more preferably having 2θ angle values ​​of 5.33±0.2, 10.61±0.2, 12.87±0.2, 15.93±0.2, 19.12±0.2, 21.79±0.2, and 26.01±0.2 degrees; even more preferably having 2θ angle values ​​of 5.33±0.2, 10.61±0.2, 12.87±0.2, 15.93±0.2, 19.12±0.2, 21.79±0.2, and 26.01±0.2 degrees; 2θ values ​​of 5.33±0.2, 10.61±0.2, 12.87±0.2, 15.26±0.2, 15.93±0.2, 18.41±0.2, 19.12±0.2, 21.30±0.2, 21.79±0.2, and 26.01±0.2 degrees; or Form F free form is characterized by a powder X-ray diffraction pattern comprising diffraction peaks having 2θ angle values ​​of 7.14±0.2, 8.45±0.2, and 24.35±0.2 degrees; preferably having 2θ angle values ​​of 7.14±0.2, 8.45±0.2, 13.29±0.2, 16.63±0.2, and 24.35±0.2 degrees; more preferably having 2θ angle values ​​of 7.14±0.2, 8.45±0.2, 13.29±0.2, 16.63±0.2, 16.96±0.2, 22.98±0.2, and 24.35±0.2 degrees; even more preferably having having 2θ values ​​of 7.14±0.2, 8.45±0.2, 13.29±0.2, 13.46±0.2, 13.92±0.2, 16.63±0.2, 16.96±0.2, 22.98±0.2, and 24.35±0.2 degrees; even more preferably having 2θ values ​​of 6.65±0.2, 7.14±0.2, 8.45±0.2, 13.29±0.2, 13.46±0.2, 13.92±0.2, 16.63±0.2, 16.96±0.2, 22.98±0.2, 24.35±0.2, and 26.09±0.2 degrees; or Form I free form is characterized by a powder X-ray diffraction pattern comprising diffraction peaks having 2θ angle values ​​of 5.84±0.2, 16.56±0.2, and 25.64±0.2 degrees; preferably having 2θ angle values ​​of 5.84±0.2, 14.04±0.2, 14.35±0.2, 16.56±0.2, and 25.64±0.2 degrees; more preferably having 2θ angle values ​​of 5.84±0.2, 14.04±0.2, 14.35±0.2, 15.85±0.2, 16.56±0.2, 25.64±0.2, and 26.06±0.2 degrees; even more preferably and 15.17 ± 0.2 degrees.

22. The crystalline form of claim 14, wherein the crystalline form is of Formula VIa wherein [solvent], s and t are as defined in claim 14; Preferably, the crystalline form is of formula VIb, VIc, VId, VIe, VIf or VIg, Where s is about 0.3, 0.33, 0.40, 0.44, 0.45, 0.50, 0.55, 0.56, 0.60, 0.63, 0.65, 0.66, 0.67, 0.70, 0.75, 0.76, 0.80, 0.85, 0.90, 0.95, 0.96, 0.97, 0.98, 0.99, 1.0、1.01、1.02、1.03、1.04、1.05、1.06、1.07、1.08、1.09、1.1、1.11、1.12、1.13、1.14、1.15、1.16、1.17、1.18、1.19、1.20、1.3、1.4、1.45、1.5、1.55、 t is about 0, 0.1, 0.14, 0.17, 0.2, 0.25, 0.3, 0.4, 0.45, 0.5, 0.50, 0.55, 0.57, 0.6, 0.65, 0.7, 0.8, 0.9, 0.95, 0.98, 1.02, 1.05, 1.08, 1.09, 1.0, 1.1, 1.11, 1.12, 1.2, 1.3, 1.4, 1.45, 1.5, 1.55, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.25, 2.3, 2.31, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3.

0.

23. The crystalline form of claim 22, selected from Type A citrate, characterized in that The following powder X-ray diffraction pattern, the powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 4.95±0.2, 6.59±0.2, 9.03±0.2, 9.98±0.2, 10.84±0.2, 13.02±0.2, 13.23±0.2, 14.56±0.2, 14.96±0.2, 15.55±0.2, 15.94±0.2, 16.71±0. 2, 17.56±0.2, 19.22±0.2, 20.09±0.2, 20.60±0.2, 21.59±0.2, 21.96±0.2, 22.33±0.2, 22.52±0.2, 23.26±0.2, 24.17±0.2, 24.41±0.2, 25.11±0.2, 26.08±0.2, 26.88±0.2, 27.43±0.2, 27.92±0.2, 30.09±0.2, and 30.75±0.2 degrees; or Form B citrate salt characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of 6.58±0.2, 8.09±0.2, 9.94±0.2, 10.91±0.2, 13.42±0.2, 14.24±0.2, 14.82±0.2, 16.21±0.2, 18.09±0.2, 18.69±0.2, 19.86±0.2, 20.30±0.2, 20.60±0.2, 21.50±0.2, 22.20±0.2, and 22.99±0.2 degrees; or Citrate Form C characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of 4.26±0.2, 5.40±0.2, 6.02±0.2, 6.61±0.2, 8.47±0.2, 10.80±0.2, 12.05±0.2, 12.70±0.2, 15.52±0.2, 16.96±0.2, 19.55±0.2, and 21.24±0.2 degrees; or Form E citrate, characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 6.75±0.2, 8.67±0.2, 9.16±0.2, 13.49±0.2, 13.73±0.2, 14.95±0.2, 16.09±0.2, 17.54±0.2, 18.42±0.2, 0.2, 18.61±0.2, 20.25±0.2, 20.64±0.2, 21.66±0.2, 22.61±0.2, 22.92±0.2, 23.58±0.2, 23.92±0.2, 25.06±0.2, 25.59±0.2, 26.11±0.2, 27.24±0.2, 28.82±0.2, 29.75±0.2, 32.31±0.2, and 33.75±0.2 degrees; or Form F citrate salt characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of 4.95±0.2, 7.24±0.2, 9.14±0.2, 9.82±0.2, 13.42±0.2, 14.05±0.2, 14.57±0.2, 14.89±0.2, 15.63±0.2, 17.10±0.2, 20.19±0.2, 21.08±0.2 and 21.92±0.2 degrees.

24. The crystalline form of claim 22, selected from Type A citrate, characterized in that A powder X-ray diffraction pattern comprising diffraction peaks having 2θ angle values ​​of 14.96±0.2, 17.56±0.2, and 26.08±0.2 degrees; preferably having 2θ angle values ​​of 14.96±0.2, 17.56±0.2, 22.33±0.2, 22.52±0.2, and 26.08±0.2 degrees; more preferably having 2θ angle values ​​of 9.03±0.2, 14.96±0.2, 15.55±0.2, 17.56±0.2, 22.33±0.2, 22.52±0.2, and 26.08±0.2 degrees; even more preferably having 2θ angle values ​​of 9.0 3±0.2, 10.84±0.2, 14.96±0.2, 15.55±0.2, 17.56±0.2, 20.60±0.2, 22.33±0.2, 22.52±0.2, and 26.08±0.2 degrees 2θ angle values; even more preferably having 9.03±0.2, 9.98±0.2, 10.84±0.2, 14.96±0.2, 15.55±0.2, 17.56±0.2, 20.60±0.2, 22.33±0.2, 22.52±0.2, 23.26±0.2, and 26.08±0.2 degrees 2θ angle values; or Form B citrate salt characterized by a powder X-ray diffraction pattern comprising diffraction peaks having 2θ angle values ​​of 6.58±0.2, 13.42±0.2, and 14.82±0.2 degrees; preferably having 2θ angle values ​​of 6.58±0.2, 13.42±0.2, 14.24±0.2, 14.82±0.2, and 19.86±0.2 degrees; more preferably having 2θ angle values ​​of 6.58±0.2, 13.42±0.2, 14.24±0.2, 14.82±0.2, 16.21±0.2, 19.86±0.2, and 20.30±0.2 degrees; even more preferably having 2θ values ​​of 6.58±0.2, 8.09±0.2, 13.42±0.2, 14.24±0.2, 14.82±0.2, 16.21±0.2, 19.86±0.2, 20.30±0.2, and 20.60±0.2 degrees; even more preferably having 2θ values ​​of 6.58±0.2, 8.09±0.2, 9.94±0.2, 13.42±0.2, 14.24±0.2, 14.82±0.2, 16.21±0.2, 18.09±0.2, 19.86±0.2, 20.30±0.2, and 20.60±0.2 degrees; or Citrate salt form, characterized by a powder X-ray diffraction pattern comprising diffraction peaks having 2θ angle values ​​of 4.26±0.2, 8.47±0.2, and 12.70±0.2 degrees; preferably having 2θ angle values ​​of 4.26±0.2, 5.40±0.2, 8.47±0.2, 12.70±0.2, and 21.24±0.2 degrees; more preferably having 2θ angle values ​​of 4.26±0.2, 5.40±0.2, 8.47±0.2, 10.80±0.2, 12.70±0.2, 21.24±0.2, and 19.55±0.2 degrees; even more preferably having having 2θ angle values ​​of 4.26±0.2, 5.40±0.2, 6.02±0.2, 8.47±0.2, 10.80±0.2, 12.70±0.2, 15.52±0.2, 16.96±0.2, 19.55±0.2, and 21.24±0.2 degrees; even more preferably having 2θ angle values ​​of 4.26±0.2, 5.40±0.2, 6.02±0.2, 8.47±0.2, 10.80±0.2, 12.70±0.2, 15.52±0.2, 16.96±0.2, 19.55±0.2, 19.91±0.2, and 21.24±0.2 degrees; or Form E citrate, characterized by a powder X-ray diffraction pattern comprising diffraction peaks having 2θ angle values ​​of 9.16±0.2, 13.49±0.2, and 13.73±0.2 degrees; preferably having 2θ angle values ​​of 9.16±0.2, 13.49±0.2, 13.73±0.2, 14.95±0.2, and 22.92±0.2 degrees; more preferably having 2θ angle values ​​of 9.16±0.2, 13.49±0.2, 13.73±0.2, 14.95±0.2, 18.42±0.2, 22.92±0.2, and 27.24±0.2 degrees; even more preferably having 2θ angle values ​​of 8.67±0.2, 9.16±0.2, 13.49±0.2, 13.73±0.2, 14.95±0.2, 18.42±0.2, 22.61±0.2, 22.92±0.2, and 27.24±0.2 degrees; even more preferably having 2θ angle values ​​of 8.67±0.2, 9.16±0.2, 13.49±0.2, 13.73±0.2, 14.95±0.2, 18.42±0.2, 21.66±0.2, 22.61±0.2, 22.92±0.2, 25.06±0.2, and 27.24±0.2 degrees; or Form F citrate salt characterized by a powder X-ray diffraction pattern comprising diffraction peaks having 2θ angle values ​​of 13.42±0.2, 14.05±0.2, and 20.19±0.2 degrees; preferably having 2θ angle values ​​of 7.24±0.2, 13.42±0.2, 14.05±0.2, 20.19±0.2, and 21.08±0.2 degrees; more preferably having 2θ angle values ​​of 7.24±0.2, 13.42±0.2, 14.05±0.2, 14.57±0.2, 17.10±0.2, 20.19±0.2, and 21.08±0.2 degrees; even more preferably having 2θ angle values ​​of 7.24±0.2, 13.42±0.2, 14.05±0.2, 14.57±0.2, 17.10±0.2, 20.19±0.2, and 21.08±0.2 degrees; Preferably, it has a 2θ angle value of 7.24±0.2, 9.82±0.2, 13.42±0.2, 14.05±0.2, 14.57±0.2, 14.89±0.2, 17.10±0.2, 20.19±0.2 and 21.08±0.2 degrees; even more preferably, it has a 2θ angle value of 4.95±0.2, 7.24±0.2, 9.82±0.2, 13.42±0.2, 14.05±0.2, 14.57±0.2, 14.89±0.2, 17.10±0.2, 20.19±0.2, 21.08±0.2 and 21.92±0.2 degrees.

25. The crystalline form of claim 14, selected from A type L-malate, characterized in that The following powder X-ray diffraction pattern, the powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 5.06±0.2, ±0.2, 6.97±0.2, 7.28±0.2, 10.09±0.2, 10.49±0.2, 13.36±0.2, 14.67±0.2, 15.13±0.2, 16.08±0.2, 17.02±0.2, 18.10±0.2, or 18.44±0.2, 18.74±0.2, 19.54±0.2, 20.05±0.2, 20.41±0.2, 21.07±0.2, 22.35±0.2, 22.82±0.2, 23.45±0.2, 23.83±0.2, 25.36±0.2, 25.72±0.2, 28.14±0.2, 29.55±0.2, 30.57±0.2, 31.22±0.2, 32.36±0.2, and 33.38±0.2 degrees; Form B succinate, characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 6.79±0.2, 9.13±0.2, 9.40±0.2, 10.22±0.2, 10.81±0.2, 12.09±0.2, 13.53±0.2, 14.25±0.2, 14.86±0.2, 15.25±0.2, 15.90±0.2, 16.55±0.2, 16.81±0.2, 1 or 7.66±0.2, 18.15±0.2, 19.06±0.2, 19.74±0.2, 20.03±0.2, 20.42±0.2, 20.71±0.2, 21.03±0.2, 22.34±0.2, 22.85±0.2, 23.22±0.2, 23.87±0.2, 24.42±0.2, 24.87±0.2, 25.19±0.2, 26.38±0.2, 26.90±0.2, 27.78±0.2, 28.13±0.2, 28.84±0.2, and 29.93±0.2 degrees; Form B fumarate salt characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 4.83±0.2, 6.66±0.2, 8.44±0.2, 9.22±0.2, 10.69±0.2, 11.60±0.2, 12.06±0.2, 12.80±0.2, 13.44±0.2, 13.86±0.2, 14.29±0.2, 15.44±0.2, 16.02±0.2, 16.33±0.2 .2, 16.95±0.2, 17.54±0.2, 18.18±0.2, 18.46±0.2, 18.97±0.2, 19.75±0.2, 20.03±0.2, 20.57±0.2, 21.14±0.2, 21.48±0.2, 22.30±0.2, 23.15±0.2, 23.96±0.2, 24.67±0.2, 24.98±0.2, 26.91±0.2, 27.85±0.2, 28.46±0.2, 31.01±0.2, 31.45±0.2, and 35.59±0.2 degrees; or D-type fumarate salt, characterized by the following powder X-ray diffraction pattern, which powder X-ray diffraction pattern comprises three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 3.29±0.2, 4.87±0.2, 6.71±0.2, 7.47±0.2, 8.08±0.2, 8.68±0.2, 10.08±0.2, 10.35±0.2, 12.67±0.2, 13.48±0.2, 14.01±0.2, 14.30±0.2, 14.83±0.

2. 2, 15.28±0.2, 15.55±0.2, 16.67±0.2, 17.31±0.2, 18.66±0.2, 18.95±0.2, 19.94±0.2, 20.05±0.2, 20.40±0.2, 21.28±0.2, 22.00±0.2, 23.10±0.2, 23.34±0.2, 24.18±0.2, 25.13±0.2, 25.83±0.2, 26.86±0.2, 30.52±0.2, 35.12±0.2, and 35.47±0.2 degrees; or A maleate salt form, characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 5.07±0.2, 8.06±0.2, 8.81±0.2, 11.70±0.2, 12.71±0.2, 13.44±0.2, 14.77±0.2, 15.25±0.2, 15.51±0.2, 16.18±0.2, 16.44±0.2, 17.32±0.2, or 0.2, 17.56±0.2, 19.02±0.2, 19.43±0.2, 20.92±0.2, 21.38±0.2, 22.20±0.2, 22.69±0.2, 23.48±0.2, 24.03±0.2, 24.80±0.2, 25.23±0.2, 25.99±0.2, 26.91±0.2, 27.37±0.2, 27.99±0.2, 29.49±0.2, 31.39±0.2, 32.33±0.2, and 33.13±0.2 degrees; A hydrochloride salt form, characterized by the following powder X-ray diffraction pattern, which powder X-ray diffraction pattern comprises three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 5.55±0.2, 8.12±0.2, 8.41±0.2, 9.29±0.2, 11.83±0.2, 12.08±0.2, 13.47±0.2, 15.42±0.2, 15.75±0.2, 16.16±0.2, 16.53±0.2, 16. .94±0.2, 18.00±0.2, 18.60±0.2, 19.84±0.2, 20.24±0.2, 21.72±0.2, 22.13±0.2, 23.08±0.2, 23.55±0.2, 24.44±0.2, 26.15±0.2, 26.38±0.2, 26.91±0.2, 27.92±0.2, 28.32±0.2, 33.12±0.2, 33.27±0.2, 34.17±0.2, and 35.28±0.2 degrees; or Form C hydrochloride is characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 6.07±0.2, 6.81±0.2, 8.31±0.2, 9.80±0.2, 12.08±0.2, 12.85±0.2, 13.17±0.2, 13.55±0.2, 13.89±0.2, 15.71±0.2, 16.11±0.2, 16.68±0.2, 18.12±0.2, 18.72±0.2 .2, 19.34±0.2, 20.31±0.2, 20.86±0.2, 22.17±0.2, 23.89±0.2, 25.07±0.2, 25.44±0.2, 26.05±0.2, 26.46±0.2, 27.12±0.2, 27.48±0.2, 28.06±0.2, 28.77±0.2, 29.13±0.2, 29.79±0.2, 30.40±0.2, 30.71±0.2, 31.97±0.2, 33.75±0.2, 35.28±0.2, and 35.74±0.2 degrees; or A sulfate salt type A, characterized by a powder X-ray diffraction pattern comprising three, four, five, six, seven, eight, nine or more diffraction peaks having 2θ angle values ​​independently selected from the group consisting of: 5.19±0.2, 6.87±0.2, 7.71±0.2, 10.28±0.2, 11.14±0.2, 13.59±0.2, 14.63±0.2, 15.35±0.2, 1 5.71±0.2, 16.17±0.2, 18.00±0.2, 18.24±0.2, 19.20±0.2, 20.23±0.2, 20.52±0.2, 21.30±0.2, 22.00±0.2, 22.30±0.2, 22.90±0.2, 24.94±0.2, 25.79±0.2, 28.52±0.2, 29.15±0.2 and 29.55±0.2 degrees.

26. The crystalline form of any one of claims 14-25, characterized essentially in that A powder X-ray diffraction pattern selected from the group consisting of: Figure 1A, Figure 2A, Figure 3A, Figure 4A, Figure 5A, Figure 7A, Figure 8A, Figure 9A, Figure 10A, Figure 11A, Figure 12A, Figure 13A, Figure 14A, Figure 15A, Figure 16A, Figure 17A, Figure 18A, Figure 19A or Figure 20A.

27. A pharmaceutical composition comprising a therapeutically effective amount of the crystalline form of any one of claims 14 to 26, and optionally one or more pharmaceutically acceptable carriers.

28. A method for treating or preventing a disorder or disease selected from an inflammatory disorder, an autoimmune disease, or cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of the crystalline form of any one of claims 14-26, or the pharmaceutical composition of claim 27.